CN113880865A - Pyrazolo [1,5-a ] pyridine compound and preparation method and application thereof - Google Patents
Pyrazolo [1,5-a ] pyridine compound and preparation method and application thereof Download PDFInfo
- Publication number
- CN113880865A CN113880865A CN202010625119.3A CN202010625119A CN113880865A CN 113880865 A CN113880865 A CN 113880865A CN 202010625119 A CN202010625119 A CN 202010625119A CN 113880865 A CN113880865 A CN 113880865A
- Authority
- CN
- China
- Prior art keywords
- compound
- alkyl
- ret
- pharmaceutically acceptable
- halo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- -1 Pyrazolo [1,5-a ] pyridine compound Chemical class 0.000 title claims description 173
- 238000002360 preparation method Methods 0.000 title abstract description 12
- 230000004927 fusion Effects 0.000 claims abstract description 38
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 33
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 26
- 201000010099 disease Diseases 0.000 claims abstract description 23
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 22
- 102100028286 Proto-oncogene tyrosine-protein kinase receptor Ret Human genes 0.000 claims abstract description 17
- 208000002551 irritable bowel syndrome Diseases 0.000 claims abstract description 13
- 230000001404 mediated effect Effects 0.000 claims abstract description 11
- 201000011510 cancer Diseases 0.000 claims abstract description 10
- 150000001875 compounds Chemical class 0.000 claims description 235
- 150000003839 salts Chemical class 0.000 claims description 78
- 125000001424 substituent group Chemical group 0.000 claims description 48
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 32
- 239000002994 raw material Substances 0.000 claims description 31
- 229910052736 halogen Inorganic materials 0.000 claims description 29
- 150000002367 halogens Chemical class 0.000 claims description 29
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 25
- 125000000623 heterocyclic group Chemical group 0.000 claims description 24
- 229910052739 hydrogen Inorganic materials 0.000 claims description 24
- 239000001257 hydrogen Substances 0.000 claims description 24
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 23
- 125000000217 alkyl group Chemical group 0.000 claims description 22
- 125000001072 heteroaryl group Chemical group 0.000 claims description 20
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 19
- 150000002431 hydrogen Chemical class 0.000 claims description 18
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 18
- 229910052801 chlorine Inorganic materials 0.000 claims description 17
- 229910052731 fluorine Inorganic materials 0.000 claims description 17
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 17
- 229910052794 bromium Inorganic materials 0.000 claims description 16
- 239000003814 drug Substances 0.000 claims description 16
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 15
- 238000005859 coupling reaction Methods 0.000 claims description 14
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 claims description 12
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 12
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims description 11
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 11
- 238000006467 substitution reaction Methods 0.000 claims description 11
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 11
- 125000006239 protecting group Chemical group 0.000 claims description 10
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 9
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 9
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 9
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 9
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 9
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 9
- 238000006268 reductive amination reaction Methods 0.000 claims description 9
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 9
- 125000003118 aryl group Chemical group 0.000 claims description 8
- 238000010511 deprotection reaction Methods 0.000 claims description 8
- 125000004076 pyridyl group Chemical group 0.000 claims description 8
- 125000003545 alkoxy group Chemical group 0.000 claims description 7
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 7
- 239000003937 drug carrier Substances 0.000 claims description 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 6
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 6
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 6
- 125000000335 thiazolyl group Chemical group 0.000 claims description 6
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims description 5
- 125000002883 imidazolyl group Chemical group 0.000 claims description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 5
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 5
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 5
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 claims description 4
- 238000006069 Suzuki reaction reaction Methods 0.000 claims description 3
- 125000001475 halogen functional group Chemical group 0.000 claims 20
- 238000004519 manufacturing process Methods 0.000 claims 4
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 abstract 2
- 150000003222 pyridines Chemical class 0.000 abstract 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 49
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 45
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 42
- 125000005843 halogen group Chemical group 0.000 description 42
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 36
- 238000005160 1H NMR spectroscopy Methods 0.000 description 35
- 210000004027 cell Anatomy 0.000 description 25
- 230000015572 biosynthetic process Effects 0.000 description 23
- 238000003786 synthesis reaction Methods 0.000 description 23
- 238000006243 chemical reaction Methods 0.000 description 22
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 17
- XIIOFHFUYBLOLW-UHFFFAOYSA-N selpercatinib Chemical compound OC(COC=1C=C(C=2N(C=1)N=CC=2C#N)C=1C=NC(=CC=1)N1CC2N(C(C1)C2)CC=1C=NC(=CC=1)OC)(C)C XIIOFHFUYBLOLW-UHFFFAOYSA-N 0.000 description 17
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 16
- 125000006413 ring segment Chemical group 0.000 description 16
- 239000000243 solution Substances 0.000 description 16
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 15
- 150000003254 radicals Chemical class 0.000 description 15
- 239000000047 product Substances 0.000 description 14
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 13
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 12
- 125000004432 carbon atom Chemical group C* 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 230000005764 inhibitory process Effects 0.000 description 12
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 12
- 229940121610 selpercatinib Drugs 0.000 description 12
- 239000002585 base Substances 0.000 description 11
- 239000000460 chlorine Substances 0.000 description 11
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 10
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 10
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 10
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 10
- 230000002829 reductive effect Effects 0.000 description 10
- 229910052717 sulfur Inorganic materials 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 9
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 9
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 9
- 229910000024 caesium carbonate Inorganic materials 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 108091000080 Phosphotransferase Proteins 0.000 description 8
- 239000003054 catalyst Substances 0.000 description 8
- 238000011580 nude mouse model Methods 0.000 description 8
- 229910052760 oxygen Inorganic materials 0.000 description 8
- 102000020233 phosphotransferase Human genes 0.000 description 8
- 239000000741 silica gel Substances 0.000 description 8
- 229910002027 silica gel Inorganic materials 0.000 description 8
- GBLBJPZSROAGMF-RWYJCYHVSA-N CO[C@@]1(CC[C@@H](CC1)C1=NC(NC2=NNC(C)=C2)=CC(C)=N1)C(=O)N[C@@H](C)C1=CC=C(N=C1)N1C=C(F)C=N1 Chemical compound CO[C@@]1(CC[C@@H](CC1)C1=NC(NC2=NNC(C)=C2)=CC(C)=N1)C(=O)N[C@@H](C)C1=CC=C(N=C1)N1C=C(F)C=N1 GBLBJPZSROAGMF-RWYJCYHVSA-N 0.000 description 7
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 7
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 7
- 125000005842 heteroatom Chemical group 0.000 description 7
- XBXCNNQPRYLIDE-UHFFFAOYSA-M n-tert-butylcarbamate Chemical compound CC(C)(C)NC([O-])=O XBXCNNQPRYLIDE-UHFFFAOYSA-M 0.000 description 7
- 125000003367 polycyclic group Chemical group 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 238000004809 thin layer chromatography Methods 0.000 description 7
- 239000003981 vehicle Substances 0.000 description 7
- CXNIUSPIQKWYAI-UHFFFAOYSA-N xantphos Chemical compound C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 CXNIUSPIQKWYAI-UHFFFAOYSA-N 0.000 description 7
- GZPHSAQLYPIAIN-UHFFFAOYSA-N 3-pyridinecarbonitrile Chemical compound N#CC1=CC=CN=C1 GZPHSAQLYPIAIN-UHFFFAOYSA-N 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 241000699660 Mus musculus Species 0.000 description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
- 229910052786 argon Inorganic materials 0.000 description 6
- 229910052799 carbon Inorganic materials 0.000 description 6
- WDVGNXKCFBOKDF-UHFFFAOYSA-N dicyclohexyl-[3,6-dimethoxy-2-[2,4,6-tri(propan-2-yl)phenyl]phenyl]phosphane Chemical compound COC1=CC=C(OC)C(C=2C(=CC(=CC=2C(C)C)C(C)C)C(C)C)=C1P(C1CCCCC1)C1CCCCC1 WDVGNXKCFBOKDF-UHFFFAOYSA-N 0.000 description 6
- 239000002552 dosage form Substances 0.000 description 6
- RPALWHLYFOTILO-UHFFFAOYSA-N heptan-2-ylcarbamic acid Chemical compound CCCCCC(C)NC(O)=O RPALWHLYFOTILO-UHFFFAOYSA-N 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 230000035772 mutation Effects 0.000 description 6
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 6
- 229910000027 potassium carbonate Inorganic materials 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- 238000007920 subcutaneous administration Methods 0.000 description 6
- 241000282414 Homo sapiens Species 0.000 description 5
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 5
- 238000005481 NMR spectroscopy Methods 0.000 description 5
- 230000002378 acidificating effect Effects 0.000 description 5
- 239000013543 active substance Substances 0.000 description 5
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 5
- 239000012044 organic layer Substances 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 238000010898 silica gel chromatography Methods 0.000 description 5
- 229910000029 sodium carbonate Inorganic materials 0.000 description 5
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 5
- CNPURSDMOWDNOQ-UHFFFAOYSA-N 4-methoxy-7h-pyrrolo[2,3-d]pyrimidin-2-amine Chemical compound COC1=NC(N)=NC2=C1C=CN2 CNPURSDMOWDNOQ-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- NFHFRUOZVGFOOS-UHFFFAOYSA-N Pd(PPh3)4 Substances [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 4
- 229910002666 PdCl2 Inorganic materials 0.000 description 4
- 101150077555 Ret gene Proteins 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- 230000008878 coupling Effects 0.000 description 4
- 238000010168 coupling process Methods 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 125000002950 monocyclic group Chemical group 0.000 description 4
- 125000002757 morpholinyl group Chemical group 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 238000010534 nucleophilic substitution reaction Methods 0.000 description 4
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 4
- 125000004193 piperazinyl group Chemical group 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 239000012279 sodium borohydride Substances 0.000 description 4
- 229910000033 sodium borohydride Inorganic materials 0.000 description 4
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 4
- 238000002054 transplantation Methods 0.000 description 4
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 3
- HDVPUYLWINHSBU-UHFFFAOYSA-N 6-[(3-fluoroazetidin-3-yl)methylamino]-4-[6-[6-[(6-methoxypyridin-3-yl)methyl]-3,6-diazabicyclo[3.1.1]heptan-3-yl]pyridin-3-yl]pyrazolo[1,5-a]pyridine-3-carbonitrile Chemical compound COC1=CC=C(CN(C(C2)C3)C2CN3C(N=C2)=CC=C2C2=CC(NCC3(CNC3)F)=CN3N=CC(C#N)=C23)C=N1 HDVPUYLWINHSBU-UHFFFAOYSA-N 0.000 description 3
- XSMKXVGNAKMLEQ-UHFFFAOYSA-N 6-bromo-4-(6-fluoropyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile Chemical compound FC1=CC=C(C=N1)C1=CC(Br)=CN2N=CC(C#N)=C12 XSMKXVGNAKMLEQ-UHFFFAOYSA-N 0.000 description 3
- AHPHVOOWKHXBEY-UHFFFAOYSA-N 6-bromo-4-[6-[6-[(6-methoxypyridin-3-yl)methyl]-3,6-diazabicyclo[3.1.1]heptan-3-yl]pyridin-3-yl]pyrazolo[1,5-a]pyridine-3-carbonitrile Chemical compound COC1=NC=C(CN2C3CC2CN(C3)C2=CC=C(C=N2)C2=CC(Br)=CN3N=CC(C#N)=C23)C=C1 AHPHVOOWKHXBEY-UHFFFAOYSA-N 0.000 description 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
- LJTVFKYAYSGFOV-UHFFFAOYSA-N C1C2CN(CC1N2)C3=NC=C(C=C3)C4=CC(=CN5C4=C(C=N5)C#N)Br Chemical compound C1C2CN(CC1N2)C3=NC=C(C=C3)C4=CC(=CN5C4=C(C=N5)C#N)Br LJTVFKYAYSGFOV-UHFFFAOYSA-N 0.000 description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 3
- 206010010774 Constipation Diseases 0.000 description 3
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 3
- 102000034615 Glial cell line-derived neurotrophic factor Human genes 0.000 description 3
- 108091010837 Glial cell line-derived neurotrophic factor Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 229910020889 NaBH3 Inorganic materials 0.000 description 3
- 206010033701 Papillary thyroid cancer Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- 125000004429 atom Chemical group 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 229910002092 carbon dioxide Inorganic materials 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000004440 column chromatography Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000011737 fluorine Substances 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 3
- XGZVUEUWXADBQD-UHFFFAOYSA-L lithium carbonate Chemical compound [Li+].[Li+].[O-]C([O-])=O XGZVUEUWXADBQD-UHFFFAOYSA-L 0.000 description 3
- 229910052808 lithium carbonate Inorganic materials 0.000 description 3
- 231100000053 low toxicity Toxicity 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 235000011056 potassium acetate Nutrition 0.000 description 3
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000000651 prodrug Substances 0.000 description 3
- 229940002612 prodrug Drugs 0.000 description 3
- 239000001632 sodium acetate Substances 0.000 description 3
- 235000017281 sodium acetate Nutrition 0.000 description 3
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- DKWZSEYPQRRCOY-UHFFFAOYSA-N tert-butyl n-heptan-2-ylcarbamate Chemical compound CCCCCC(C)NC(=O)OC(C)(C)C DKWZSEYPQRRCOY-UHFFFAOYSA-N 0.000 description 3
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 208000030045 thyroid gland papillary carcinoma Diseases 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- 125000005940 1,4-dioxanyl group Chemical group 0.000 description 2
- LXQMHOKEXZETKB-UHFFFAOYSA-N 1-amino-2-methylpropan-2-ol Chemical compound CC(C)(O)CN LXQMHOKEXZETKB-UHFFFAOYSA-N 0.000 description 2
- LVYJIIRJQDEGBR-UHFFFAOYSA-N 1-fluoro-2-iodoethane Chemical compound FCCI LVYJIIRJQDEGBR-UHFFFAOYSA-N 0.000 description 2
- 125000004066 1-hydroxyethyl group Chemical group [H]OC([H])([*])C([H])([H])[H] 0.000 description 2
- OVRWUZYZECPJOB-UHFFFAOYSA-N 2,2-difluoroethanamine Chemical compound NCC(F)F OVRWUZYZECPJOB-UHFFFAOYSA-N 0.000 description 2
- KDSNLYIMUZNERS-UHFFFAOYSA-N 2-methylpropanamine Chemical compound CC(C)CN KDSNLYIMUZNERS-UHFFFAOYSA-N 0.000 description 2
- 125000001698 2H-pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 2
- WNEODWDFDXWOLU-QHCPKHFHSA-N 3-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-[(2s)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]pyridin-2-yl]amino]-6-oxopyridin-3-yl]pyridin-2-yl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one Chemical compound C([C@@H](N(CC1)C=2C=NC(NC=3C(N(C)C=C(C=3)C=3C(=C(N4C(C5=CC=6CC(C)(C)CC=6N5CC4)=O)N=CC=3)CO)=O)=CC=2)C)N1C1COC1 WNEODWDFDXWOLU-QHCPKHFHSA-N 0.000 description 2
- QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 description 2
- CJUABCUFAIRVMS-UHFFFAOYSA-N 4-[6-(3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl]-6-(2,2-difluoroethylamino)pyrazolo[1,5-a]pyridine-3-carbonitrile Chemical compound N#CC1=C(C(C2=CC=C(N3CC(C4)NC4C3)N=C2)=CC(NCC(F)F)=C2)N2N=C1 CJUABCUFAIRVMS-UHFFFAOYSA-N 0.000 description 2
- SXIFAEWFOJETOA-UHFFFAOYSA-N 4-hydroxy-butyl Chemical group [CH2]CCCO SXIFAEWFOJETOA-UHFFFAOYSA-N 0.000 description 2
- 125000001826 4H-pyranyl group Chemical group O1C(=CCC=C1)* 0.000 description 2
- DDWAUXRNZSOQQE-UHFFFAOYSA-N 6-(2,2-difluoroethylamino)-4-[6-[6-[(2-fluoro-5-methoxyphenyl)methyl]-3,6-diazabicyclo[3.1.1]heptan-3-yl]pyridin-3-yl]pyrazolo[1,5-a]pyridine-3-carbonitrile Chemical compound COC(C=C1)=CC(CN(C(C2)C3)C2CN3C(N=C2)=CC=C2C2=CC(NCC(F)F)=CN3N=CC(C#N)=C23)=C1F DDWAUXRNZSOQQE-UHFFFAOYSA-N 0.000 description 2
- JSAURMVXOKLEFA-UHFFFAOYSA-N 6-(2-fluoroethylamino)-4-[6-[6-[(3-fluoro-4-methoxyphenyl)methyl]-3,6-diazabicyclo[3.1.1]heptan-3-yl]pyridin-3-yl]pyrazolo[1,5-a]pyridine-3-carbonitrile Chemical compound COC(C=CC(CN(C(C1)C2)C1CN2C(N=C1)=CC=C1C1=CC(NCCF)=CN2N=CC(C#N)=C12)=C1)=C1F JSAURMVXOKLEFA-UHFFFAOYSA-N 0.000 description 2
- RWAMJKCNAWKVFF-UHFFFAOYSA-N 6-(2-fluoroethylamino)-4-[6-[6-[(4-methoxyphenyl)methyl]-3,6-diazabicyclo[3.1.1]heptan-3-yl]pyridin-3-yl]pyrazolo[1,5-a]pyridine-3-carbonitrile Chemical compound COC1=CC=C(CN(C(C2)C3)C2CN3C(N=C2)=CC=C2C2=CC(NCCF)=CN3N=CC(C#N)=C23)C=C1 RWAMJKCNAWKVFF-UHFFFAOYSA-N 0.000 description 2
- STZFIUBDGVLJDE-UHFFFAOYSA-N 6-(cyanomethylamino)-4-[6-[6-[(6-methoxypyridin-3-yl)methyl]-3,6-diazabicyclo[3.1.1]heptan-3-yl]pyridin-3-yl]pyrazolo[1,5-a]pyridine-3-carbonitrile Chemical compound COC1=CC=C(CN(C(C2)C3)C2CN3C(N=C2)=CC=C2C2=CC(NCC#N)=CN3N=CC(C#N)=C23)C=N1 STZFIUBDGVLJDE-UHFFFAOYSA-N 0.000 description 2
- GWUFFTZXAJTWAD-UHFFFAOYSA-N 6-[(3-fluoroazetidin-3-yl)methylamino]-4-[6-[6-[(3-fluoro-4-methoxyphenyl)methyl]-3,6-diazabicyclo[3.1.1]heptan-3-yl]pyridin-3-yl]pyrazolo[1,5-a]pyridine-3-carbonitrile Chemical compound COC(C=CC(CN(C(C1)C2)C1CN2C(N=C1)=CC=C1C1=CC(NCC2(CNC2)F)=CN2N=CC(C#N)=C12)=C1)=C1F GWUFFTZXAJTWAD-UHFFFAOYSA-N 0.000 description 2
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 2
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- CJLHTKGWEUGORV-UHFFFAOYSA-N Artemin Chemical compound C1CC2(C)C(O)CCC(=C)C2(O)C2C1C(C)C(=O)O2 CJLHTKGWEUGORV-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 238000011729 BALB/c nude mouse Methods 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- AUQMYVRQBKKUJD-UHFFFAOYSA-N CC(C)CNC1=CN2C(=C(C=N2)C#N)C(=C1)C3=CN=C(C=C3)N4CC5CC(C4)N5CC6=CN=C(C=C6)OC Chemical compound CC(C)CNC1=CN2C(=C(C=N2)C#N)C(=C1)C3=CN=C(C=C3)N4CC5CC(C4)N5CC6=CN=C(C=C6)OC AUQMYVRQBKKUJD-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- 239000002176 L01XE26 - Cabozantinib Substances 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 208000037196 Medullary thyroid carcinoma Diseases 0.000 description 2
- 208000006876 Multiple Endocrine Neoplasia Type 2b Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 102000001839 Neurturin Human genes 0.000 description 2
- 108010015406 Neurturin Proteins 0.000 description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical class [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- YKIOKAURTKXMSB-UHFFFAOYSA-N adams's catalyst Chemical compound O=[Pt]=O YKIOKAURTKXMSB-UHFFFAOYSA-N 0.000 description 2
- 150000001335 aliphatic alkanes Chemical group 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium group Chemical group [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- 230000003698 anagen phase Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 125000002393 azetidinyl group Chemical group 0.000 description 2
- 125000004069 aziridinyl group Chemical group 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229960001292 cabozantinib Drugs 0.000 description 2
- ONIQOQHATWINJY-UHFFFAOYSA-N cabozantinib Chemical compound C=12C=C(OC)C(OC)=CC2=NC=CC=1OC(C=C1)=CC=C1NC(=O)C1(C(=O)NC=2C=CC(F)=CC=2)CC1 ONIQOQHATWINJY-UHFFFAOYSA-N 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229910002091 carbon monoxide Inorganic materials 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 2
- 238000001212 derivatisation Methods 0.000 description 2
- 125000004772 dichloromethyl group Chemical group [H]C(Cl)(Cl)* 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000012065 filter cake Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 125000002541 furyl group Chemical group 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 230000009036 growth inhibition Effects 0.000 description 2
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 2
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 2
- 125000002632 imidazolidinyl group Chemical group 0.000 description 2
- 125000001967 indiganyl group Chemical group [H][In]([H])[*] 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 2
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 2
- 125000001786 isothiazolyl group Chemical group 0.000 description 2
- 125000000842 isoxazolyl group Chemical group 0.000 description 2
- 229960003784 lenvatinib Drugs 0.000 description 2
- WOSKHXYHFSIKNG-UHFFFAOYSA-N lenvatinib Chemical compound C=12C=C(C(N)=O)C(OC)=CC2=NC=CC=1OC(C=C1Cl)=CC=C1NC(=O)NC1CC1 WOSKHXYHFSIKNG-UHFFFAOYSA-N 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 125000001715 oxadiazolyl group Chemical group 0.000 description 2
- 125000002971 oxazolyl group Chemical group 0.000 description 2
- 125000003566 oxetanyl group Chemical group 0.000 description 2
- 125000004430 oxygen atom Chemical group O* 0.000 description 2
- ZRSNZINYAWTAHE-UHFFFAOYSA-N p-methoxybenzaldehyde Chemical compound COC1=CC=C(C=O)C=C1 ZRSNZINYAWTAHE-UHFFFAOYSA-N 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 125000003386 piperidinyl group Chemical group 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 2
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 2
- 125000003226 pyrazolyl group Chemical group 0.000 description 2
- 125000002098 pyridazinyl group Chemical group 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 230000000171 quenching effect Effects 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 2
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000007909 solid dosage form Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 2
- 125000003554 tetrahydropyrrolyl group Chemical group 0.000 description 2
- 125000005958 tetrahydrothienyl group Chemical group 0.000 description 2
- 125000003831 tetrazolyl group Chemical group 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 125000001113 thiadiazolyl group Chemical group 0.000 description 2
- 125000005458 thianyl group Chemical group 0.000 description 2
- 125000001544 thienyl group Chemical group 0.000 description 2
- 125000002053 thietanyl group Chemical group 0.000 description 2
- 201000002510 thyroid cancer Diseases 0.000 description 2
- 208000013818 thyroid gland medullary carcinoma Diseases 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 125000004306 triazinyl group Chemical group 0.000 description 2
- 125000001425 triazolyl group Chemical group 0.000 description 2
- 125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- OJBYZWHAPXIJID-UHFFFAOYSA-N (6-fluoropyridin-3-yl)boronic acid Chemical compound OB(O)C1=CC=C(F)N=C1 OJBYZWHAPXIJID-UHFFFAOYSA-N 0.000 description 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 1
- LNDGACQEAYKNOI-UHFFFAOYSA-N 1,1,1-trifluoro-4-iodobutane Chemical compound FC(F)(F)CCCI LNDGACQEAYKNOI-UHFFFAOYSA-N 0.000 description 1
- 125000005918 1,2-dimethylbutyl group Chemical group 0.000 description 1
- LDMOEFOXLIZJOW-UHFFFAOYSA-N 1-dodecanesulfonic acid Chemical compound CCCCCCCCCCCCS(O)(=O)=O LDMOEFOXLIZJOW-UHFFFAOYSA-N 0.000 description 1
- URBUZQPPQLQHBZ-UHFFFAOYSA-N 1-fluoro-3-iodopropane Chemical group FCCCI URBUZQPPQLQHBZ-UHFFFAOYSA-N 0.000 description 1
- KIPSRYDSZQRPEA-UHFFFAOYSA-N 2,2,2-trifluoroethanamine Chemical compound NCC(F)(F)F KIPSRYDSZQRPEA-UHFFFAOYSA-N 0.000 description 1
- DPQNQLKPUVWGHE-UHFFFAOYSA-N 2,2,3,3,3-pentafluoropropan-1-amine Chemical compound NCC(F)(F)C(F)(F)F DPQNQLKPUVWGHE-UHFFFAOYSA-N 0.000 description 1
- UBBBLLSKHCENQZ-UHFFFAOYSA-N 2,3-difluoro-4-methoxybenzaldehyde Chemical compound COC1=CC=C(C=O)C(F)=C1F UBBBLLSKHCENQZ-UHFFFAOYSA-N 0.000 description 1
- DCGKDDVUUMOTDH-UHFFFAOYSA-N 2,5-difluoro-4-methoxybenzaldehyde Chemical compound COC1=CC(F)=C(C=O)C=C1F DCGKDDVUUMOTDH-UHFFFAOYSA-N 0.000 description 1
- IDWZESHNJMMWTR-UHFFFAOYSA-N 2-(1,2,4-triazol-1-yl)ethanamine Chemical compound NCCN1C=NC=N1 IDWZESHNJMMWTR-UHFFFAOYSA-N 0.000 description 1
- ATCZRYPJBPXFIN-UHFFFAOYSA-N 2-(1,2,4-triazol-4-yl)ethanamine Chemical compound NCCN1C=NN=C1 ATCZRYPJBPXFIN-UHFFFAOYSA-N 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- YWGKOEQZKMSICW-UHFFFAOYSA-N 2-chloro-4-methoxybenzaldehyde Chemical compound COC1=CC=C(C=O)C(Cl)=C1 YWGKOEQZKMSICW-UHFFFAOYSA-N 0.000 description 1
- 125000006176 2-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 description 1
- UNWQNFJBBWXFBG-UHFFFAOYSA-N 2-fluoro-4-methoxybenzaldehyde Chemical compound COC1=CC=C(C=O)C(F)=C1 UNWQNFJBBWXFBG-UHFFFAOYSA-N 0.000 description 1
- DKIQXHIAEMGZGO-UHFFFAOYSA-N 2-fluoro-5-methoxybenzaldehyde Chemical compound COC1=CC=C(F)C(C=O)=C1 DKIQXHIAEMGZGO-UHFFFAOYSA-N 0.000 description 1
- YCIRHAGYEUJTFH-UHFFFAOYSA-N 2-imidazol-1-ylethanamine Chemical compound NCCN1C=CN=C1 YCIRHAGYEUJTFH-UHFFFAOYSA-N 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- 125000005916 2-methylpentyl group Chemical group 0.000 description 1
- SLRMQYXOBQWXCR-UHFFFAOYSA-N 2154-56-5 Chemical compound [CH2]C1=CC=CC=C1 SLRMQYXOBQWXCR-UHFFFAOYSA-N 0.000 description 1
- NGZVNONVXYLYQW-UHFFFAOYSA-N 3,3,3-trifluoropropan-1-amine Chemical compound NCCC(F)(F)F NGZVNONVXYLYQW-UHFFFAOYSA-N 0.000 description 1
- RKATWUBDSJHPEV-UHFFFAOYSA-N 3,3-difluorocyclobutan-1-amine Chemical compound NC1CC(F)(F)C1 RKATWUBDSJHPEV-UHFFFAOYSA-N 0.000 description 1
- KBSLGHDKSCGXKQ-UHFFFAOYSA-N 3,5-difluoro-4-methoxybenzaldehyde Chemical compound COC1=C(F)C=C(C=O)C=C1F KBSLGHDKSCGXKQ-UHFFFAOYSA-N 0.000 description 1
- PJAIMBYNTXNOCN-UHFFFAOYSA-N 3,6-dibromo-1h-indole Chemical compound BrC1=CC=C2C(Br)=CNC2=C1 PJAIMBYNTXNOCN-UHFFFAOYSA-N 0.000 description 1
- WYVGYYIZXPXHAZ-UHFFFAOYSA-N 3-chloro-4-methoxybenzaldehyde Chemical compound COC1=CC=C(C=O)C=C1Cl WYVGYYIZXPXHAZ-UHFFFAOYSA-N 0.000 description 1
- SOQCZBSZZLWDGU-UHFFFAOYSA-N 3-fluoro-4-methoxybenzaldehyde Chemical compound COC1=CC=C(C=O)C=C1F SOQCZBSZZLWDGU-UHFFFAOYSA-N 0.000 description 1
- 125000005917 3-methylpentyl group Chemical group 0.000 description 1
- QUYFSHOLLKVPGX-UHFFFAOYSA-N 3-methylsulfonylpropan-1-amine Chemical compound CS(=O)(=O)CCCN QUYFSHOLLKVPGX-UHFFFAOYSA-N 0.000 description 1
- FBKJJSFJKWOLQA-UHFFFAOYSA-N 4,6-dibromopyrazolo[1,5-a]pyridine-3-carbonitrile Chemical compound BrC=1C=2N(C=C(C=1)Br)N=CC=2C#N FBKJJSFJKWOLQA-UHFFFAOYSA-N 0.000 description 1
- BBQMURAQGGKHNN-UHFFFAOYSA-N 4-(difluoromethoxy)-3-fluorobenzaldehyde Chemical compound FC(F)OC1=CC=C(C=O)C=C1F BBQMURAQGGKHNN-UHFFFAOYSA-N 0.000 description 1
- ZWCXOJYJJINQGU-UHFFFAOYSA-N 4-(difluoromethoxy)benzaldehyde Chemical compound FC(F)OC1=CC=C(C=O)C=C1 ZWCXOJYJJINQGU-UHFFFAOYSA-N 0.000 description 1
- YIKDRXNCTJGQGO-UHFFFAOYSA-N 4-[6-(3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl]-6-(2-fluoroethylamino)pyrazolo[1,5-a]pyridine-3-carbonitrile Chemical compound N#CC1=C(C(C2=CC=C(N3CC(C4)NC4C3)N=C2)=CC(NCCF)=C2)N2N=C1 YIKDRXNCTJGQGO-UHFFFAOYSA-N 0.000 description 1
- NKZTZYFQTAFWJY-UHFFFAOYSA-N 4-[6-[6-[(3,5-difluoro-4-methoxyphenyl)methyl]-3,6-diazabicyclo[3.1.1]heptan-3-yl]pyridin-3-yl]-6-(2-fluoroethylamino)pyrazolo[1,5-a]pyridine-3-carbonitrile Chemical compound COC(C(F)=CC(CN(C(C1)C2)C1CN2C(N=C1)=CC=C1C1=CC(NCCF)=CN2N=CC(C#N)=C12)=C1)=C1F NKZTZYFQTAFWJY-UHFFFAOYSA-N 0.000 description 1
- RMKCVZCSCKZQGV-UHFFFAOYSA-N 4-[6-[6-[(5-chloro-6-methoxypyridin-3-yl)methyl]-3,6-diazabicyclo[3.1.1]heptan-3-yl]pyridin-3-yl]-6-(2-fluoroethylamino)pyrazolo[1,5-a]pyridine-3-carbonitrile Chemical compound COC(N=CC(CN(C(C1)C2)C1CN2C(N=C1)=CC=C1C1=CC(NCCF)=CN2N=CC(C#N)=C12)=C1)=C1Cl RMKCVZCSCKZQGV-UHFFFAOYSA-N 0.000 description 1
- KIOUUGRBGRCRSM-UHFFFAOYSA-N 4-[6-[6-[[4-(difluoromethoxy)phenyl]methyl]-3,6-diazabicyclo[3.1.1]heptan-3-yl]pyridin-3-yl]-6-(2-fluoroethylamino)pyrazolo[1,5-a]pyridine-3-carbonitrile Chemical compound N#CC1=C(C(C2=CC=C(N3CC(C4)N(CC(C=C5)=CC=C5OC(F)F)C4C3)N=C2)=CC(NCCF)=C2)N2N=C1 KIOUUGRBGRCRSM-UHFFFAOYSA-N 0.000 description 1
- SRLYWFLNTODCEU-UHFFFAOYSA-N 4-[6-[6-[[6-(difluoromethoxy)pyridin-3-yl]methyl]-3,6-diazabicyclo[3.1.1]heptan-3-yl]pyridin-3-yl]-6-(2-fluoroethylamino)pyrazolo[1,5-a]pyridine-3-carbonitrile Chemical compound N#CC1=C(C(C2=CC=C(N3CC(C4)N(CC(C=N5)=CC=C5OC(F)F)C4C3)N=C2)=CC(NCCF)=C2)N2N=C1 SRLYWFLNTODCEU-UHFFFAOYSA-N 0.000 description 1
- IZBHWLYKWKYMOY-UHFFFAOYSA-N 5-chloro-6-methoxypyridine-3-carbaldehyde Chemical compound COC1=NC=C(C=O)C=C1Cl IZBHWLYKWKYMOY-UHFFFAOYSA-N 0.000 description 1
- BKATVSAQJLGKJC-UHFFFAOYSA-N 5-fluoro-6-methoxypyridine-3-carbaldehyde Chemical compound COC1=NC=C(C=O)C=C1F BKATVSAQJLGKJC-UHFFFAOYSA-N 0.000 description 1
- MNFVVGDATVIPNE-UHFFFAOYSA-N 6-(2-fluoroethylamino)-4-[6-[6-[(2-fluoro-4-methoxyphenyl)methyl]-3,6-diazabicyclo[3.1.1]heptan-3-yl]pyridin-3-yl]pyrazolo[1,5-a]pyridine-3-carbonitrile Chemical compound COC1=CC(F)=C(CN(C(C2)C3)C2CN3C(N=C2)=CC=C2C2=CC(NCCF)=CN3N=CC(C#N)=C23)C=C1 MNFVVGDATVIPNE-UHFFFAOYSA-N 0.000 description 1
- NRGBKYVUEUMGTE-UHFFFAOYSA-N 6-(difluoromethoxy)pyridine-3-carbaldehyde Chemical compound FC(F)OC1=CC=C(C=O)C=N1 NRGBKYVUEUMGTE-UHFFFAOYSA-N 0.000 description 1
- YPKLQWJADAGQFX-UHFFFAOYSA-N 6-[(3,3-difluorocyclobutyl)amino]-4-[6-[6-[(6-methoxypyridin-3-yl)methyl]-3,6-diazabicyclo[3.1.1]heptan-3-yl]pyridin-3-yl]pyrazolo[1,5-a]pyridine-3-carbonitrile Chemical compound COC1=CC=C(CN(C(C2)C3)C2CN3C(N=C2)=CC=C2C2=CC(NC(C3)CC3(F)F)=CN3N=CC(C#N)=C23)C=N1 YPKLQWJADAGQFX-UHFFFAOYSA-N 0.000 description 1
- LMXHIKFNZVQRTF-UHFFFAOYSA-N 6-bromo-4-[6-[6-[(3-fluoro-4-methoxyphenyl)methyl]-3,6-diazabicyclo[3.1.1]heptan-3-yl]pyridin-3-yl]pyrazolo[1,5-a]pyridine-3-carbonitrile Chemical compound COC(C=CC(CN(C(C1)C2)C1CN2C(N=C1)=CC=C1C1=CC(Br)=CN2N=CC(C#N)=C12)=C1)=C1F LMXHIKFNZVQRTF-UHFFFAOYSA-N 0.000 description 1
- CTAIEPPAOULMFY-UHFFFAOYSA-N 6-methoxypyridine-3-carbaldehyde Chemical compound COC1=CC=C(C=O)C=N1 CTAIEPPAOULMFY-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 101150051159 ARTN gene Proteins 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 102100026376 Artemin Human genes 0.000 description 1
- 101710205806 Artemin Proteins 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- QWLWLZLMJQOQCD-UHFFFAOYSA-N CC(C)(C)OC(=O)NC1=CN2C(=C(C=N2)C#N)C(=C1)C3=CN=C(C=C3)N4CC5CC(C4)N5CC6=CN=C(C=C6)OC Chemical compound CC(C)(C)OC(=O)NC1=CN2C(=C(C=N2)C#N)C(=C1)C3=CN=C(C=C3)N4CC5CC(C4)N5CC6=CN=C(C=C6)OC QWLWLZLMJQOQCD-UHFFFAOYSA-N 0.000 description 1
- 102000000905 Cadherin Human genes 0.000 description 1
- 108050007957 Cadherin Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 102100031048 Coiled-coil domain-containing protein 6 Human genes 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 102100029505 E3 ubiquitin-protein ligase TRIM33 Human genes 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 201000001342 Fallopian tube cancer Diseases 0.000 description 1
- 208000013452 Fallopian tube neoplasm Diseases 0.000 description 1
- 206010016935 Follicular thyroid cancer Diseases 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 241000282575 Gorilla Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000777370 Homo sapiens Coiled-coil domain-containing protein 6 Proteins 0.000 description 1
- 101000634991 Homo sapiens E3 ubiquitin-protein ligase TRIM33 Proteins 0.000 description 1
- 101001050559 Homo sapiens Kinesin-1 heavy chain Proteins 0.000 description 1
- SHBUUTHKGIVMJT-UHFFFAOYSA-N Hydroxystearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OO SHBUUTHKGIVMJT-UHFFFAOYSA-N 0.000 description 1
- 241000282620 Hylobates sp. Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 102100023422 Kinesin-1 heavy chain Human genes 0.000 description 1
- 239000002118 L01XE12 - Vandetanib Substances 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000009018 Medullary thyroid cancer Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 206010073148 Multiple endocrine neoplasia type 2A Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 208000014174 Oesophageal disease Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 102000038030 PI3Ks Human genes 0.000 description 1
- 108091007960 PI3Ks Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 101150044960 PSPN gene Proteins 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 241001504519 Papio ursinus Species 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 102100036660 Persephin Human genes 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 241000282405 Pongo abelii Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 206010036772 Proctalgia Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 102000052575 Proto-Oncogene Human genes 0.000 description 1
- 108700020978 Proto-Oncogene Proteins 0.000 description 1
- 229910019020 PtO2 Inorganic materials 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- 229920002253 Tannate Polymers 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 108091008605 VEGF receptors Proteins 0.000 description 1
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- PNDPGZBMCMUPRI-XXSWNUTMSA-N [125I][125I] Chemical compound [125I][125I] PNDPGZBMCMUPRI-XXSWNUTMSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 229940022663 acetate Drugs 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- DFNYGALUNNFWKJ-UHFFFAOYSA-N aminoacetonitrile Chemical compound NCC#N DFNYGALUNNFWKJ-UHFFFAOYSA-N 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 235000019568 aromas Nutrition 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 238000011914 asymmetric synthesis Methods 0.000 description 1
- 230000035578 autophosphorylation Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000005874 benzothiadiazolyl group Chemical group 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 208000024330 bloating Diseases 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 150000005829 chemical entities Chemical class 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000012069 chiral reagent Substances 0.000 description 1
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 125000003678 cyclohexadienyl group Chemical group C1(=CC=CCC1)* 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 150000004656 dimethylamines Chemical class 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 230000007783 downstream signaling Effects 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- 208000028299 esophageal disease Diseases 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 150000003947 ethylamines Chemical class 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 125000005519 fluorenylmethyloxycarbonyl group Chemical group 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000001215 fluorescent labelling Methods 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229940050411 fumarate Drugs 0.000 description 1
- 201000000117 functional diarrhea Diseases 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 229940072106 hydroxystearate Drugs 0.000 description 1
- 229960003943 hypromellose Drugs 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 229940044173 iodine-125 Drugs 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 229940099584 lactobionate Drugs 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Substances [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 241001515942 marmosets Species 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 150000003956 methylamines Chemical class 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 229940124303 multikinase inhibitor Drugs 0.000 description 1
- 206010051747 multiple endocrine neoplasia Diseases 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-M naphthalene-1-sulfonate Chemical compound C1=CC=C2C(S(=O)(=O)[O-])=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-M 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 230000009437 off-target effect Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 229960003552 other antineoplastic agent in atc Drugs 0.000 description 1
- 229940039748 oxalate Drugs 0.000 description 1
- LPNBBFKOUUSUDB-UHFFFAOYSA-N p-toluic acid Chemical compound CC1=CC=C(C(O)=O)C=C1 LPNBBFKOUUSUDB-UHFFFAOYSA-N 0.000 description 1
- MUJIDPITZJWBSW-UHFFFAOYSA-N palladium(2+) Chemical compound [Pd+2] MUJIDPITZJWBSW-UHFFFAOYSA-N 0.000 description 1
- NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 108010070453 persephin Proteins 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 208000028591 pheochromocytoma Diseases 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 125000000612 phthaloyl group Chemical group C(C=1C(C(=O)*)=CC=CC1)(=O)* 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 238000009666 routine test Methods 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- OKODKVMXHLUQSW-JITBQSAISA-M sodium;(e)-4-hydroxy-4-oxobut-2-enoate;octadecanoic acid Chemical compound [Na+].OC(=O)\C=C\C([O-])=O.CCCCCCCCCCCCCCCCCC(O)=O OKODKVMXHLUQSW-JITBQSAISA-M 0.000 description 1
- 238000003797 solvolysis reaction Methods 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229940086735 succinate Drugs 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- OUFBVDKNEWUFHP-UHFFFAOYSA-N tert-butyl 3,6-diazabicyclo[3.1.1]heptane-6-carboxylate Chemical compound C1C2N(C(=O)OC(C)(C)C)C1CNC2 OUFBVDKNEWUFHP-UHFFFAOYSA-N 0.000 description 1
- HRNGGAXXQINCHD-UHFFFAOYSA-N tert-butyl 3-(aminomethyl)-3-fluoroazetidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CC(F)(CN)C1 HRNGGAXXQINCHD-UHFFFAOYSA-N 0.000 description 1
- TYJRXGDXGJDMTH-UHFFFAOYSA-N tert-butyl 3-[[[3-cyano-4-[6-[6-[(6-methoxypyridin-3-yl)methyl]-3,6-diazabicyclo[3.1.1]heptan-3-yl]pyridin-3-yl]pyrazolo[1,5-a]pyridin-6-yl]amino]methyl]-3-fluoroazetidine-1-carboxylate Chemical compound CC(C)(C)OC(N(C1)CC1(CNC1=CN2N=CC(C#N)=C2C(C2=CC=C(N3CC(C4)N(CC(C=N5)=CC=C5OC)C4C3)N=C2)=C1)F)=O TYJRXGDXGJDMTH-UHFFFAOYSA-N 0.000 description 1
- NIJQFLWLVOKBKT-UHFFFAOYSA-N tert-butyl N-[3-cyano-4-[6-[6-[(6-methoxypyridin-3-yl)methyl]-3,6-diazabicyclo[3.1.1]heptan-3-yl]pyridin-3-yl]pyrazolo[1,5-a]pyridin-6-yl]-N-(2-fluoroethyl)carbamate Chemical compound CC(C)(C)OC(N(CCF)C1=CN2N=CC(C#N)=C2C(C2=CC=C(N3CC(C4)N(CC(C=N5)=CC=C5OC)C4C3)N=C2)=C1)=O NIJQFLWLVOKBKT-UHFFFAOYSA-N 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical group C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 125000004588 thienopyridyl group Chemical group S1C(=CC2=C1C=CC=N2)* 0.000 description 1
- 208000030901 thyroid gland follicular carcinoma Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical class CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 229940070710 valerate Drugs 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- UHTHHESEBZOYNR-UHFFFAOYSA-N vandetanib Chemical compound COC1=CC(C(/N=CN2)=N/C=3C(=CC(Br)=CC=3)F)=C2C=C1OCC1CCN(C)CC1 UHTHHESEBZOYNR-UHFFFAOYSA-N 0.000 description 1
- 229960000241 vandetanib Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 229910052727 yttrium Inorganic materials 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to a pyrazole [1,5-a ] represented by the following general formula (I)]Pyridine compounds, preparation method, pharmaceutical composition and application thereof, wherein R in the formula1、R2、R3、R4、R5X, Y, Z are as defined in the specification. The pyrazole [1,5-a ] of the present invention]The pyridine compounds can effectively inhibit wild-type RET, mutant RET, especially G810R mutant RET, and RET fusion such as KIF5B-RET and CCDC6-RET, and have good safety, and can be used for treating diseases mediated by RET, such as cancer and irritable bowel syndrome.
Description
Technical Field
The invention belongs to the field of medicines, and particularly relates to a pyrazolo [1,5-a ] pyridine compound serving as a RET inhibitor, a preparation method of the compound, a pharmaceutical composition containing the compound, and application of the compound and the pharmaceutical composition in treatment of RET-mediated diseases.
Background
The transfected rearranged gene, RET (rearranged along transforming transformation) gene, is a protooncogene and is located on chromosome 10. The RET protein encoded by the RET gene is a Receptor Tyrosine Kinase (RTK) present on cell membranes and belongs to a member of the cadherin superfamily. Ligands for RET are the glial-derived neurotrophic factor family, including glial cell-derived neurotrophic factor (GDNF), neurturin (nrtn), artemin (artn), and persephin (pspn). When ligand binds to the extracellular domain of RET, it leads to dimerization of RET and autophosphorylation of the intracellular kinase domain, thus activating RET, and then initiating multiple downstream signaling pathways such as RAS/MAPK/ERK, PI3K/AKT, JAK/STAT, etc. to play roles in cell proliferation, migration and differentiation.
Abnormalities in the RET gene (including fusion and point mutations) lead to overactivation of the RET signaling pathway and uncontrolled cell growth, and are closely associated with the development and progression of a variety of tumors. The incidence of RET gene fusion in non-small cell lung cancer (NSCLC) patients is about 1% -2%, and the incidence in Papillary Thyroid Cancer (PTC) patients is 10% -20%; the most common fusion partners include KIF5B, TRIM33, CCDC6, and NCOA 4. The incidence of RET gene point mutations in Medullary Thyroid Carcinoma (MTC) patients is around 60%; common mutation sites include C634R, M918T, V804L, V804M, G810R, and the like. Furthermore, in colorectal, breast, pancreatic and other cancers, low frequency RET fusions are also observed; RET fusion was also observed in NSCLC patients carrying EGFR mutations.
At present, targeting drugs aiming at RET genes comprise (1) multikinase inhibitor drugs targeting multiple targets, such as Cabozantinib (Cabozantinib), Vandetanib (Vandernib), Lenvatinib (Lenvatinib) and the like, although the activity of RET can be inhibited, due to low selectivity, especially serious toxic and side effects related to VEGFR inhibition generally occur due to off-target effect, and clinical application is limited; (2) the drugs for selectively targeting RET genes, such as BLU-667 and LOXO-292, have good inhibitory activity on wild type and mutant RET (such as M918T, V804L/M and the like), common KIF5B-RET fusion and CCDC6-RET fusion and the like, and have relatively low toxicity.
The BLU-667 is disclosed in WO2017079140A1 and developed by Blueprint pharmaceuticals, having the following structure, and has been filed to FDA for new drug marketing applications. LOXO-292 is disclosed in WO2018071447A1, developed by Loxo Oncology, and has the following structure, which was approved by the FDA to be marketed in 5 months of 2020; however, in the literature (Journal of clinical Oncology, Volume 15, Issue 4, April 2020, Pages 541 and 549), it is reported that RET fusion NSCLC patients develop RET G810R resistance mutation, resulting in LOXO-292 resistance.
In addition, abnormal RET expression and/or activity has also been demonstrated in gastrointestinal disorders such as Irritable Bowel Syndrome (IBS).
The development of new potent, low toxicity selective small molecule inhibitors of RET for the treatment of RET mediated diseases is a need in humans.
Disclosure of Invention
The invention provides a pyrazolo [1,5-a ] pyridine compound with a novel structure or a pharmaceutically acceptable salt thereof, which is a selective RET inhibitor, can effectively inhibit wild RET, mutant RET, particularly G810R mutant RET, and RET fusion such as KIF5B-RET and CCDC6-RET, has good safety, and can be used for treating diseases mediated by RET, such as cancer and irritable bowel syndrome.
The invention provides a compound shown in the following formula (I) or a pharmaceutically acceptable salt thereof,
wherein:
x is selected from CR6Or N;
y is selected from CR6Or N;
z is selected from CR6Or N;
wherein 0, 1 or 2 of X, Y, Z are N;
R1selected from hydrogen, 6-10 membered aryl or 5-12 membered heteroaryl, wherein each of said 6-10 membered aryl or 5-12 membered heteroaryl is optionally substituted with 1, 2, 3 or 4 substituents each independently selected from hydroxy, halogen, C1-6Alkyl radical, C1-6Alkoxy, halo C1-6Alkyl, halo C1-6Alkoxy, hydroxy C1-6Alkyl, 3-6 membered cycloalkyl, cyano, -NR7R8or-O- (CH)2)n-NR7R8Substituted with the substituent(s);
R2selected from hydrogen, C1-4Alkyl or halo C1-4An alkyl group;
R3selected from hydrogen, C1-6Alkyl, 3-6 membered cycloalkyl, 3-8 membered heterocyclyl or 5-12 membered heteroaryl, wherein said C1-6Alkyl, 3-6 membered cycloalkyl, 3-8 membered heterocyclyl or 5-12 membered heteroaryl are each optionally substituted with 1, 2, 3 or 4 substituents each independently selected from halogen, C1-4Alkyl radical, C1-4Alkoxy, halo C1-4Alkyl, halo C1-4Alkoxy, cyano, hydroxy C1-4Alkyl, -C (═ O) -NR7R8、-SO2-C1-4Alkyl, 5-6 membered heteroaryl or 3-6 membered heterocyclyl, wherein said 5-6 membered heteroaryl or 3-6 membered heterocyclyl are each optionally substituted with 1, 2 or 3 substituents each independently selected from halogen, hydroxy, C1-4Alkyl radical, C1-4Alkoxy- (CH)2)m-or-C (═ O) -C1-4Alkyl is substituted by a substituent;
R4selected from hydrogen, C1-4Alkyl or halo C1-4An alkyl group;
R5selected from hydrogen, halogen, cyano, C1-4Alkyl or halo C1-4An alkyl group;
each R6Independently selected from H, C1-4Alkyl radical, C1-4Alkoxy, halo C1-4Alkyl or halogen;
each R7Independently selected from H, C1-4Alkyl or halo C1-4An alkyl group;
each R8Independently selected from H, C1-4Alkyl or halo C1-4An alkyl group;
n is selected from 1, 2 or 3;
m is selected from 0, 1, 2 or 3.
In another embodiment of the compound of formula (I) or a pharmaceutically acceptable salt thereof according to the invention, X is selected from CR6Or N, Y is selected from CR6Or N, Z are selected from CR6Or N, wherein 0 or 1 of X, Y, Z is N; wherein each R6Independently selected from H, C1-4Alkyl, halo C1-4Alkyl or halogen.
In another embodiment of the compound of the formula (I) according to the invention or a pharmaceutically acceptable salt thereof, wherein X is CR6Y is CR6Z is CR6(ii) a Wherein each R6Independently selected from H, C1-4Alkyl, halo C1-4Alkyl or halogen.
In another embodiment of the compound of the formula (I) according to the invention or a pharmaceutically acceptable salt thereof, wherein X is CR6Y is CR6Z is CR6(ii) a Wherein each R6Independently selected from H, methyl, ethyl, monofluoromethyl, difluoromethyl, trifluoromethyl, CF3CH2-、CHF2CH2-、 CH2FCH2-, F, Cl or Br.
In another embodiment of the compound of the formula (I) according to the invention or a pharmaceutically acceptable salt thereof, wherein X is CR6Y is CR6Z is CR6Wherein each R is6Is H.
In another embodiment of the compounds of formula (I) or pharmaceutically acceptable salts thereof of the present invention, R as described above1Selected from phenyl or 5-6 membered heteroaryl, wherein said phenyl or 5-6 membered heteroaryl is each optionally substituted with 1, 2 or 3 substituents each independently selected from hydroxy, halogen, C1-6Alkyl radical, C1-6Alkoxy, halo C1-6Alkyl, halo C1-6Alkoxy or cyano.
The compound of formula (I) according to the invention or a pharmaceutical preparation thereofIn another embodiment of the above acceptable salts, the above R1Selected from phenyl or 5-6 membered heteroaryl, wherein said phenyl or 5-6 membered heteroaryl is each optionally substituted with 1, 2 or 3 substituents each independently selected from hydroxy, halogen, C1-4Alkyl radical, C1-4Alkoxy, halo C1-4Alkyl or halo C1-4Substituted by a substituent of alkoxy.
In another embodiment of the compounds of formula (I) or pharmaceutically acceptable salts thereof of the present invention, R as described above1Selected from phenyl, pyridyl, pyrimidinyl, pyrazinyl, pyrrolyl, imidazolyl or thiazolyl, wherein said phenyl, pyridyl, pyrimidinyl, pyrazinyl, pyrrolyl, imidazolyl or thiazolyl is each optionally substituted with 1, 2 or 3 groups each independently selected from hydroxy, halogen, C1-4Alkyl radical, C1-4Alkoxy, halo C1-4Alkyl or halo C1-4Substituted by a substituent of alkoxy.
In another embodiment of the compounds of formula (I) or pharmaceutically acceptable salts thereof of the present invention, R as described above1Selected from phenyl, Wherein said phenyl group, Each optionally substituted by 1, 2 or 3 groups each independently selected from hydroxy, F, Cl, Br, C1-4Alkyl radical, C1-4Alkoxy, halo C1-4Alkyl or halo C1-4Substituted by a substituent of alkoxy.
In another embodiment of the compounds of formula (I) or pharmaceutically acceptable salts thereof of the present invention, R as described above1Selected from phenyl, Wherein said phenyl group, Each optionally substituted with 1, 2 or 3 substituents each independently selected from hydroxy, F, Cl, Br, methyl, ethyl, n-propyl, isopropyl, methoxy, ethoxy, n-propoxy, isopropoxy, monofluoromethyl, difluoromethyl, trifluoromethyl, CF3CH2-、CHF2CH2-、 CH2FCH2-, monofluoromethoxy, difluoromethoxy, trifluoromethoxy, CF3CH2-O-、 CHF2CH2-O-or CH2FCH2-O-is substituted.
In another embodiment of the compounds of formula (I) or pharmaceutically acceptable salts thereof of the present invention, R as described above1Is selected from phenyl or pyridyl, wherein said phenyl or pyridyl is each optionally substituted with 1, 2 or 3 groups each independently selected from hydroxy, halogen, C1-4Alkyl radical, C1-4Alkoxy, halo C1-4Alkyl or halo C1-4Substituted by a substituent of alkoxy.
In another embodiment of the compounds of formula (I) or pharmaceutically acceptable salts thereof of the present invention, R as described above1Selected from phenyl,Wherein said phenyl group, Each optionally substituted by 1, 2 or 3 substituents each independently selected from hydroxy, F, Cl, Br, methyl, ethyl, n-propyl, iso-propylPropyl, methoxy, ethoxy, n-propoxy, isopropoxy, monofluoromethyl, difluoromethyl, trifluoromethyl, CF3CH2-、CHF2CH2-、CH2FCH2-, monofluoromethoxy, difluoromethoxy, trifluoromethoxy, CF3CH2-O-、CHF2CH2-O-or CH2FCH2-O-is substituted.
In another embodiment of the compounds of formula (I) or pharmaceutically acceptable salts thereof of the present invention, R as described above1Is selected from
In another embodiment of the compounds of formula (I) or pharmaceutically acceptable salts thereof of the present invention, R as described above1Is selected from
In another embodiment of the compounds of formula (I) or pharmaceutically acceptable salts thereof of the present invention, R as described above2Selected from hydrogen or C1-4An alkyl group.
In another embodiment of the compounds of formula (I) or pharmaceutically acceptable salts thereof of the present invention, R as described above2Is hydrogen.
In another embodiment of the compounds of formula (I) or pharmaceutically acceptable salts thereof of the present invention, R as described above4Selected from hydrogen or C1-4An alkyl group.
In another embodiment of the present invention, the compound of formula (I) or a pharmaceutically acceptable salt thereofIn (1), the above R4Is hydrogen.
In another embodiment of the compounds of formula (I) or pharmaceutically acceptable salts thereof of the present invention, R as described above5Selected from hydrogen, halogen or cyano.
In another embodiment of the compounds of formula (I) or pharmaceutically acceptable salts thereof of the present invention, R as described above5Is cyano.
In another embodiment of the compounds of formula (I) or pharmaceutically acceptable salts thereof of the present invention, R as described above3Selected from hydrogen, C1-6Alkyl or 3-6 membered cycloalkyl, wherein said C is1-6Alkyl or 3-6 membered cycloalkyl each optionally substituted by 1, 2 or 3 substituents each independently selected from halogen, C1-4Alkyl radical, C1-4Alkoxy, halo C1-4Alkyl, halo C1-4Alkoxy, cyano, hydroxy, -SO2-C1-4Alkyl, 5-6 membered heteroaryl or 3-6 membered heterocyclyl, wherein each of said 5-6 membered heteroaryl or 3-6 membered heterocyclyl is optionally substituted with 1, 2 or 3 substituents each independently selected from halogen, hydroxy or C1-4Alkyl substituents.
In another embodiment of the compounds of formula (I) or pharmaceutically acceptable salts thereof of the present invention, R as described above3Selected from hydrogen, C1-4Alkyl, cyclopropyl, cyclobutyl or cyclopentyl, wherein said C1-4Alkyl, cyclopropyl, cyclobutyl or cyclopentyl is each optionally substituted by 1, 2 or 3 substituents each independently selected from F, Cl, Br, C1-4Alkyl radical, C1-4Alkoxy, halo C1-4Alkyl, halo C1-4Alkoxy, cyano, hydroxy, -SO2-C1-4Alkyl, aryl, heteroaryl, and heteroaryl, Wherein said substituent is substituted, wherein Each optionally substituted by 1, 2 or 3 substituents each independently selected from F, Cl, Br, hydroxy or C1-4Alkyl substituents.
In another embodiment of the compounds of formula (I) or pharmaceutically acceptable salts thereof of the present invention, R as described above3Selected from hydrogen, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, cyclopropyl, cyclobutyl or cyclopentyl, wherein the methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, cyclopropyl, cyclobutyl or cyclopentyl are each optionally substituted with 1, 2 or 3 substituents each independently selected from F, Cl, Br, methyl, ethyl, methoxy, ethoxy, monofluoromethyl, difluoromethyl, trifluoromethyl, CF, and3CH2-、CHF2CH2-、 CH2FCH2-, monofluoromethoxy, difluoromethoxy, trifluoromethoxy, CF3CH2-O-、 CHF2CH2-O-、CH2FCH2-O-, cyano, hydroxy, -SO2-CH3、-SO2-CH2CH3、 Wherein said substituent is substituted, wherein Each optionally substituted with 1, 2 or 3 substituents each independently selected from F, Cl, Br, hydroxy, methyl or ethyl.
In another embodiment of the compounds of formula (I) or pharmaceutically acceptable salts thereof of the present invention, R as described above3Selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, monofluoromethyl, difluoromethyl, trifluoromethyl,
In another embodiment of the compounds of formula (I) or pharmaceutically acceptable salts thereof of the present invention, R as described above3Selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, monofluoromethyl, difluoromethyl, trifluoromethyl,
The present invention also provides a compound as shown below or a pharmaceutically acceptable salt thereof:
the compounds of formula (I) of the present invention may be prepared by various synthetic methods known to those skilled in the art, without particular limitation, for example, by the methods of scheme one or scheme two provided herein, it is to be understood that the synthetic methods of the compounds of formula (I) of the present invention are not limited to scheme one or scheme two, and that conventional substitutions and modifications may be made by those skilled in the art.
The first scheme is as follows:
wherein R is1、R2、R3、R4、R5X, Y, Z are as defined above; l is a leaving group, such as halogen, preferably I; p is an amino-protecting group, each P may be the same or different, and each P is independently preferably a tert-butoxycarbonyl group (Boc), a benzyloxycarbonyl group (Cbz), or a benzyl group (Bn).
Taking a compound a-1 and a compound a-2 as initial raw materials, and carrying out Suzuki coupling reaction to obtain a compound a-3; carrying out substitution reaction on the compound a-3 and the compound a-4 to obtain an intermediate 1; deprotection of the intermediate 1 to obtain a compound a-5; carrying out reductive amination reaction on the compound a-5 and the compound a-6 to obtain an intermediate 2; intermediate 2 andcoupling reaction is carried out to obtain the compound shown in the formula (I).
Or, in the preparation of R4When the compound of formula (I) is H, the intermediate 2 may be reacted with P-NH2Carrying out coupling reaction to obtain a compound a-7; compounds a-7 and R3-L undergoes a substitution reaction to give a compound a-8; deprotection of the compound a-8 can obtain the compound shown in the formula (I).
In the first scheme, the Suzuki coupling reaction is carried out in the presence of a base and a catalyst, wherein the catalyst includes but is not limited to Pd (dppf) Cl2、Pd(PPh3)4、PdCl2And the like, the base includes, but is not limited to, cesium carbonate, potassium carbonate, sodium carbonate, lithium carbonate, potassium acetate, sodium acetate, potassium t-butoxide, t-butanolSodium and the like; the substitution reaction to prepare intermediate 1 and compounds a-8 is carried out in the presence of a base including, but not limited to, cesium carbonate, potassium carbonate, sodium carbonate, triethylamine, and the like; deprotection of intermediate 1 and Compounds a-8 is under acidic conditions or in catalyst/H2In the presence of acidic conditions including but not limited to HCl/MeOH, HCl/EA, trifluoroacetic acid and the like, and catalysts including but not limited to Pd/C, PdCl2/C、Pd(OH)2C, etc.; the reductive amination reaction to prepare intermediate 2 is carried out in the presence of a reducing agent including, but not limited to, NaBH (OAc)3、NaBH4、NaBH3CN and the like; intermediate 2 andor P-NH2The coupling reaction takes place in the presence of a catalyst, including but not limited to Pd, a base2(dba)3/Xantphos、Pd2(dba)3/Brettphos、Pd(OAc)2Xanthphos, and the like, including but not limited to cesium carbonate, potassium carbonate, sodium carbonate, lithium carbonate, potassium acetate, sodium acetate, potassium tert-butoxide, sodium tert-butoxide, and the like.
Scheme II:
wherein R is1、R2、R3、R4、R5X, Y, Z are as defined above; l is a leaving group, such as halogen, preferably I; p is an amino-protecting group, each P may be the same or different, and each P is independently preferably a tert-butoxycarbonyl group (Boc), a benzyloxycarbonyl group (Cbz), or a benzyl group (Bn).
Intermediate 1 andcarrying out coupling reaction to obtain a compound b-1; deprotection of compound b-1 gives intermediate 3; and carrying out reductive amination reaction on the intermediate 3 and the compound a-6 to obtain the compound shown in the formula (I).
Or, in the preparation of R4When the compound of formula (I) is H, the intermediate 1 may be reacted with P-NH2Carrying out coupling reaction to obtain a compound b-2; compounds b-2 and R3-L undergoes a substitution reaction to give a compound b-3; deprotecting compound b-3 to obtain intermediate 3; and carrying out reductive amination reaction on the intermediate 3 and the compound a-6 to obtain the compound shown in the formula (I).
In scheme two above, intermediate 1 is reacted withOr P-NH2The coupling reaction takes place in the presence of a catalyst, including but not limited to Pd, a base2(dba)3/Xantphos、 Pd2(dba)3/Brettphos、Pd(OAc)2Xanthphos, and the like, including but not limited to cesium carbonate, potassium carbonate, sodium carbonate, lithium carbonate, potassium acetate, sodium acetate, potassium tert-butoxide, sodium tert-butoxide, and the like; deprotection of Compounds b-1 and b-3 is under acidic conditions or in catalyst/H2In the presence of acidic conditions including but not limited to HCl/MeOH, HCl/EA, trifluoroacetic acid and the like, and catalysts including but not limited to Pd/C, PdCl2/C、Pd(OH)2C, etc.; the reductive amination of intermediate 3 with compound a-6 is carried out in the presence of a reducing agent including, but not limited to, NaBH (OAc)3、NaBH4、NaBH3CN and the like; the substitution reaction to prepare compound b-3 is carried out in the presence of a base including, but not limited to, cesium carbonate, potassium carbonate, sodium carbonate, triethylamine, and the like.
The invention also provides intermediate compounds which comprise a compound a-7, a compound a-8, a compound b-1, a compound b-2, a compound b-3 and an intermediate 3 shown in the following structures,
wherein R is1、R2、R3、R4、R5X, Y, Z are as defined above; p isThe amino-protecting group, each P, which may be the same or different, is preferably a tert-butyloxycarbonyl group (Boc), a benzyloxycarbonyl group (Cbz), or a benzyl group (Bn), each independently.
The present invention still further provides intermediate compounds of the structure:
the invention also provides a pharmaceutical composition comprising the compound or the pharmaceutically acceptable salt thereof and an optional pharmaceutically acceptable carrier. The pharmaceutical composition of the present invention includes an optional pharmaceutically acceptable carrier, which means that the composition may or may not include a pharmaceutically acceptable carrier.
The invention also provides application of the compound or the pharmaceutically acceptable salt thereof or the pharmaceutical composition thereof in preparing a medicament for treating diseases mediated by RET.
The invention also provides application of the compound or the pharmaceutically acceptable salt thereof or the pharmaceutical composition thereof in preparing a medicament for treating diseases mediated by RET. Wherein the RET comprises wild type RET, mutant RET, RET fusion, the mutant RET comprises but is not limited to G810R mutant RET, M918T mutant RET, V804L mutant RET, V804M mutant RET, preferably G810R mutant RET, the RET fusion comprises but is not limited to KIF5B-RET fusion, CCDC6-RET fusion, preferably KIF5B-RET fusion; the diseases include cancer and irritable bowel syndrome.
The invention also provides the application of the compound or the pharmaceutically acceptable salt thereof or the pharmaceutical composition thereof in preparing medicines for treating diseases mediated by wild type RET, mutant RET and RET fusion; wherein the mutant RET includes, but is not limited to, G810R mutant RET, M918T mutant RET, V804L mutant RET, V804M mutant RET, preferably G810R mutant RET, and the RET fusion includes, but is not limited to, KIF5B-RET fusion, CCDC6-RET fusion, preferably KIF5B-RET fusion; the diseases include cancer and irritable bowel syndrome.
The invention also provides application of the compound or the pharmaceutically acceptable salt thereof or the pharmaceutical composition thereof in preparing medicines for treating RET-mediated cancer and irritable bowel syndrome. Wherein the RET comprises wild type RET, mutant RET, RET fusion, the mutant RET comprises but is not limited to G810R mutant RET, M918T mutant RET, V804L mutant RET, V804M mutant RET, preferably G810R mutant RET, the RET fusion comprises but is not limited to KIF5B-RET fusion, CCDC6-RET fusion, preferably KIF5B-RET fusion.
The invention also provides application of the compound or the pharmaceutically acceptable salt thereof or the pharmaceutical composition thereof in preparing medicines for treating cancers mediated by wild-type RET, mutant RET and RET fusion and irritable bowel syndrome. Wherein the mutant RET includes, but is not limited to, G810R mutant RET, M918T mutant RET, V804L mutant RET, V804M mutant RET, preferably G810R mutant RET; such RET fusions include, but are not limited to, KIF5B-RET fusion, CCDC6-RET fusion, and preferably KIF5B-RET fusion.
The invention also provides application of the compound or the pharmaceutically acceptable salt thereof or the pharmaceutical composition thereof in preparing a medicament for treating cancer.
The invention also provides application of the compound or the pharmaceutically acceptable salt thereof or the pharmaceutical composition thereof in preparing a medicament for treating irritable bowel syndrome.
The present invention also provides a method for treating a disease mediated by RET, which comprises administering to a patient in need thereof an effective amount of the above-mentioned compound or a pharmaceutically acceptable salt thereof or a pharmaceutical composition thereof. Wherein the RET comprises wild type RET, mutant RET, RET fusion, the mutant RET comprises but is not limited to G810R mutant RET, M918T mutant RET, V804L mutant RET, V804M mutant RET, the RET fusion comprises but is not limited to KIF5B-RET fusion, CCDC6-RET fusion; the diseases include cancer and irritable bowel syndrome.
The present invention also provides a method for treating cancer, which comprises administering an effective amount of the above-mentioned compound or a pharmaceutically acceptable salt thereof or a pharmaceutical composition thereof to a patient in need thereof.
The present invention also provides a method for treating irritable bowel syndrome, which comprises administering an effective amount of the above-mentioned compound or a pharmaceutically acceptable salt thereof or a pharmaceutical composition thereof to a patient in need thereof.
The cancers of the present invention include, but are not limited to, small cell lung cancer, non-small cell lung cancer, papillary thyroid cancer, medullary thyroid cancer, follicular thyroid cancer, undifferentiated thyroid cancer, recurrent thyroid cancer, multiple endocrine neoplasia type 2A or 2B (MEN 2A or MEN2B, respectively), hepatocellular carcinoma, lung cancer, head and neck cancer, glioma, neuroblastoma, pheochromocytoma, colorectal cancer, testicular cancer, prostate cancer, fallopian tube cancer, ovarian cancer, cervical cancer, breast cancer, and pancreatic cancer.
Irritable bowel syndrome according to the present invention, including but not limited to diarrhea predominant, constipation predominant or alternating pattern of bowel movements, functional bloating, functional constipation, functional diarrhea, non-specific functional bowel disorder, functional abdominal pain syndrome, chronic idiopathic constipation, functional esophageal disorder, functional gastroduodenal disorder, functional anorectal pain, and inflammatory bowel disease.
The invention also comprises pharmaceutically acceptable salts of the compounds shown in the formula (I). The term "pharmaceutically acceptable salt" refers to acid addition salts or base addition salts of the compounds of the present invention that are relatively non-toxic. The acid addition salts are salts of the compounds of formula (I) of the present invention with suitable inorganic or organic acids, which salts may be prepared by reacting a compound of formula (I) with a suitable organic or inorganic acid in a suitable solvent. Representative acid addition salts include hydrobromide, hydrochloride, sulfate, bisulfate, sulfite, acetate, oxalate, valerate, oleate, palmitate, stearate, metasilicate, borate, benzoate, lactate, nitrate, phosphate, biphosphate, carbonate, bicarbonate, toluate, citrate, maleate, fumarate, succinate, malate, ascorbate, tannate, pamoate, alginate, naphthalenesulfonate, tartrate, benzoate, methanesulfonate, p-toluenesulfonate, and the likeSulfonate, gluconate, lactobionate, laurylsulfonate, and the like. The base addition salts are salts of the compounds of formula (I) with suitable inorganic or organic bases, which salts may be prepared by reacting a compound of formula (I) with a suitable inorganic or organic base in a suitable solvent. Representative base addition salts include, for example, those formed with alkali metal, alkaline earth metal, quaternary ammonium cations such as sodium, lithium, potassium, calcium, magnesium, tetramethylquaternary ammonium, tetraethylquaternary ammonium, and the like; amine salts, including with ammonia (NH)3) And salts of primary, secondary or tertiary amines, such as methylamine salt, dimethylamine salt, trimethylamine salt, triethylamine salt, ethylamine salt, etc.
In addition to salt forms, the compounds provided herein also exist in prodrug forms. Prodrugs described herein refer to compounds that can be converted under physiological conditions or by solvolysis to the biologically active compounds described herein, such as compounds of formula (I). Thus, the term "prodrug" refers to a precursor of a pharmaceutically acceptable biologically active compound.
The compounds of the present invention may contain unnatural proportions of atomic isotopes at one or more of the atoms that constitute such compounds. For example, compounds may be labelled with radioactive isotopes, such as deuterium (D), tritium (I), (II), (III), (IV)3H) Iodine-125 (125I) Or C-14(14C) In that respect All isotopic variations of the compounds of the present invention, whether radioactive or not, are intended to be encompassed within the scope of the present invention.
The compounds of the present invention may exist in specific geometric or stereoisomeric forms. The present invention contemplates all such compounds, including cis and trans isomers, (-) -and (+) -enantiomers, (R) -and (S) -enantiomers, diastereomers, (D) -isomers, (L) -isomers, as well as racemic and other mixtures thereof, such as enantiomerically or diastereomerically enriched mixtures, all of which are within the scope of the present invention. All such isomers, as well as mixtures thereof, are included within the scope of the present invention.
Optically active (R) -and (S) -isomers as well as D and L isomers can be prepared by chiral synthesis or chiral reagents or other conventional techniques. If one of the enantiomers of a compound of the invention is desired, it can be prepared by asymmetric synthesis or derivatization with a chiral auxiliary, wherein the resulting diastereomeric mixture is separated and the auxiliary group is cleaved to provide the pure desired enantiomer. Alternatively, when the molecule contains a basic functional group (e.g., amino) or an acidic functional group (e.g., carboxyl), diastereomeric salts are formed with an appropriate optically active acid or base, followed by diastereomeric resolution by conventional methods known in the art, and the pure enantiomers are recovered. Furthermore, separation of enantiomers and diastereomers is typically accomplished by using chromatography employing a chiral stationary phase, optionally in combination with chemical derivatization (e.g., carbamate formation from amines).
In the present invention, "pharmaceutically acceptable" refers to those compounds, materials, compositions, and dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
In the present invention, a "pharmaceutically acceptable carrier" refers to one or more compatible solid or liquid fillers or gel materials that are suitable for human use and must be of sufficient purity and sufficiently low toxicity. By "compatible" is meant herein that the components of the composition are capable of being blended with the compounds of the present invention and with each other without significantly diminishing the efficacy of the compounds. Examples of pharmaceutically acceptable carrier moieties are cellulose and its derivatives (e.g. sodium carboxymethylcellulose, ethylcellulose, methylcellulose, hypromellose and its derivatives, cellulose acetate and the like), gelatin, talc, solid lubricants (e.g. stearic acid, magnesium/calcium stearate, hydrogenated vegetable oils, sodium fumarate stearate), calcium sulfate, vegetable oils (e.g. soybean oil, sesame oil, peanut oil, olive oil and the like), polyols (e.g. propylene glycol, glycerol, mannitol, sorbitol and the like), emulsifiers, wetting agents (e.g. sodium lauryl sulfate), colorants, flavors, stabilizers, antioxidants, preservatives and the like.
In the present invention, an "effective amount" with respect to a drug or pharmacologically active agent refers to a sufficient amount of the drug or pharmacologically active agent that is non-toxic but achieves the desired effect. The effective amount to be determined varies from person to person, depending on the age, weight and condition of the patient and also on the particular active substance, and an appropriate effective amount in an individual case can be determined by a person skilled in the art in the light of routine tests.
As used herein, "active ingredient," "active substance," or "active agent" refers to a chemical entity that is effective in treating a target disorder, disease, or condition.
In the context of the present invention, a "patient", "individual" or "subject" includes a human, animal, vertebrate, mammal, rodent (e.g., guinea pig, hamster, rat, mouse), murine (e.g., mouse), canine (e.g., dog), primate, ape (e.g., monkey or ape), monkey (e.g., marmoset, baboon), ape (e.g., gorilla, chimpanzee, orangutan, gibbon). In some embodiments, a "patient" is a human.
In the present invention, "treatment" means administration of a compound or formulation of the present invention to prevent, ameliorate or eliminate a disease or one or more symptoms associated with the disease, and includes:
(i) preventing the occurrence of a disease or condition in a mammal, particularly when such mammal is susceptible to the disease or condition, but has not yet been diagnosed as having the disease or condition;
(ii) inhibiting a disease or disease state, i.e., arresting its development;
(iii) alleviating the disease or condition, i.e., causing regression of the disease or condition.
As used herein, "optional," "optional," or "optionally" means that the subsequently described event or circumstance may or may not occur, and that the description includes instances where the event or circumstance occurs and instances where it does not. For example, "optionally substituted with R" means that it may or may not be substituted with R, and the description includes both substitution with R and non-substitution with R.
In the present invention, "substituted" or "substituted" means that one or more hydrogen atoms, preferably 1 to 5 hydrogen atoms, more preferably 1, 2, 3 or 4 hydrogen atoms in the group are substituted independently of each other by a corresponding number of substituents, as long as the substituted compound is stable.
In the present invention, "independently" or "independent" refers to where more than one substituent is selected from a large number of possible substituents, which may be the same or different. For example, "RxSelected from-OR OR-N (R)2(ii) a Each R is independently selected from H or C1-C4Alkyl ", wherein each substituent R is independent, which may be the same or different.
In the present invention, "group" and "group" represent a monovalent group or a divalent or more group corresponding to the valence as required, and for example, "cycloalkyl" includes a monovalent group obtained by removing one hydrogen atom therefrom, and also includes a divalent or more group obtained by removing two or more hydrogen atoms from the same carbon atom or two or more different carbon atoms therein. "cycloalkyl" is naturally a monovalent group when it is a terminal group, and is a divalent or higher group when it is a linking group in the structure. In the present invention, a monovalent or divalent or higher group generally means a monovalent group or a divalent group, but the group may be higher in valence (for example, trivalent, tetravalent, pentavalent, hexavalent, etc.) as required.
In the present invention, "Cd-e"(d and e represent integers of 1 or more, and d < e) includes any particular case of d to e carbons, e.g. C1-6Comprising C1、C2、C3、C4、C5、C6Also included are any ranges of d to e, e.g. C1-6Comprising C1-3、C1-4、C1-5、C2-5、C2-4、 C3-6Etc.; similarly, "d-e-membered" (d and e represent integers of 1 or more, d < e) means that the number of atoms on the ring is d to e, for example, 3-6 membered rings including 3-membered rings, 4-membered rings, 5-membered rings, 6-membered rings, and any of d to eBy way of example, a 3-6 membered ring includes a 3-4 membered ring, a 3-5 membered ring, a 4-6 membered ring, a 4-5 membered ring, and the like.
In the present invention, "halogen" means fluorine, chlorine, bromine, iodine, etc., preferably fluorine, chlorine, bromine, more preferably fluorine, chlorine.
In the present invention, "C1-6Alkyl "refers to a straight or branched chain alkyl derived from an alkane moiety containing 1 to 6 carbon atoms by removal of one or more hydrogen atoms, specifically, C1-6Alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, 2-methylbutyl, neopentyl, 1-ethylpropyl, n-hexyl, isohexyl, 4-methylpentyl, 3-methylpentyl, 2-methylpentyl, 1-methylpentyl, 3-dimethylbutyl, 2-dimethylbutyl, 1-dimethylbutyl, 1, 2-dimethylbutyl, 1, 3-dimethylbutyl, 2-ethylbutyl, 1-methyl-2-methylpropyl, and the like; said "C1-4Alkyl "refers to a straight or branched chain alkyl derived from an alkane moiety containing 1 to 4 carbon atoms by removal of one or more hydrogen atoms, specifically, C1-4Alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl.
In the present invention, "C1-6Alkoxy "means" C "as defined above1-6Alkyl "radicals attached to the rest of the molecule via an oxygen atom, i.e." C1-6alkyl-O- "groups including, but not limited to, e.g., methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy, tert-butoxy, neopentyloxy, n-hexyloxy, and the like; said "C1-4Alkoxy "means" C "as defined above1-4Alkyl "radicals attached to the rest of the molecule via an oxygen atom, i.e." C1-4alkyl-O- "groups include, but are not limited to, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy, tert-butoxy.
In the present invention, "halogeno C1-6Alkyl "means one or more (preferably 1 to 5, more preferably)Optionally 1, 2 or 3) halogen atoms substituted for "C" as defined above1-6A group formed by a corresponding number of hydrogen atoms on the alkyl group "wherein each halogen atom may be the same or different when substituted with a plurality of halogen atoms, in particular, a halogenated C1-6Alkyl includes, but is not limited to, monofluoromethyl, trifluoromethyl, trichloromethyl, difluoromethyl, dichloromethyl, monochloromethyl, CF3CH2-、CHF2CH2-、CH2FCH2-、 CH3CHF-、CH2FCHCl-、CF3CH2CH2-、CF3CH2CH(CH3)CH2-and the like; "halo C1-4Alkyl "means that one or more (preferably 1 to 5, more preferably 1, 2 or 3) halogen atoms are substituted for" C "as defined above1-4The corresponding number of hydrogen atoms in the alkyl group "wherein each halogen atom may be the same or different when substituted with multiple halogen atoms, specifically, but not limited to, monofluoromethyl, trifluoromethyl, trichloromethyl, difluoromethyl, dichloromethyl, chloromethyl, CF3CH2-、CHF2CH2-、CH2FCH2-、CH3CHF-、CH2FCHCl-, etc.
In the present invention, "halogeno C1-6Alkoxy "means that one or more (preferably 1 to 5, more preferably 1, 2 or 3) halogen atoms are substituted for" C "as defined above1-6The corresponding number of hydrogen atoms in the alkoxy group "wherein each halogen atom may be the same or different when substituted with a plurality of halogen atoms, specifically, but not limited to, monofluoromethoxy, trifluoromethoxy, trichloromethoxy, difluoromethoxy, dichloromethoxy, monochloromethoxy, CF3CH2-O-、CHF2CH2-O-、 CH2FCH2-O-、CF3CH2CH2-O-and the like; "halo C1-4Alkoxy "means that one or more (preferably 1 to 5, more preferably 1, 2 or 3) halogen atoms are substituted for" C "as defined above1-4The corresponding number of hydrogen atoms on the alkoxy radical ", wherein when there is a plurality of halogen atoms substitutedEach halogen atom may be the same or different, and specifically includes, but is not limited to, monofluoromethoxy, trifluoromethoxy, trichloromethoxy, difluoromethoxy, dichloromethoxy, monochloromethoxy, CF3CH2-O-、CHF2CH2-O-、CH2FCH2-O-、CF3CH2CH2-O-, etc.
In the present invention, "hydroxy group C1-6Alkyl "means that one or more (preferably 1, 2 or 3) hydroxy groups are substituted for" C "as defined above1-6The radicals formed by the corresponding number of hydrogen atoms in an alkyl group "include, but are not limited to, hydroxymethyl, 1-hydroxyethyl, 2-hydroxypropyl, 3-hydroxypropyl, 2, 3-dihydroxypropyl, 2-hydroxy-2-methylpropyl, 4-hydroxybutyl, 5-hydroxypentyl, 2-hydroxymethyl-1-hydroxypropyl; "hydroxy group C1-4Alkyl "means that one or more (preferably 1, 2 or 3) hydroxy groups are substituted for" C "as defined above1-4The radicals formed by the corresponding number of hydrogen atoms in an alkyl group "include, but are not limited to, hydroxymethyl, 1-hydroxyethyl, 2-hydroxypropyl, 3-hydroxypropyl, 2, 3-dihydroxypropyl, 2-hydroxy-2-methylpropyl, 4-hydroxybutyl.
In the present invention, "ring atom" means an atom forming a ring, including but not limited to C, N, O, P and S; "Ring carbon atom" means ring atom C; "Ring heteroatom" means a ring atom other than a C atom, including but not limited to ring atoms N, O, P and S.
In the present invention, "cycloalkyl" refers to a saturated or partially unsaturated cyclic hydrocarbon group, which may be a monovalent group or a group more than divalent, and includes monocyclic cycloalkyl groups and polycyclic cycloalkyl groups, including spirocyclic cycloalkyl groups, fused-ring cycloalkyl groups, and bridged-ring cycloalkyl groups, wherein "spirocyclic cycloalkyl groups" refers to polycyclic cycloalkyl groups in which single rings share one ring carbon atom (referred to as a spiro atom) between them, wherein "fused-ring cycloalkyl groups" refers to polycyclic cycloalkyl groups in which each ring in the group shares an adjacent pair of ring carbon atoms with other rings, and wherein "bridged-ring cycloalkyl groups" refers to polycyclic cycloalkyl groups in which any two rings share two ring carbon atoms which are not directly connected. In the present invention, "3-6 membered cycloalkyl" refers to cycloalkyl groups comprising 3 to 6 ring carbon atoms, including but not limited to cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cyclohexadienyl and the like.
In the present invention, "heterocyclyl" means a saturated or partially unsaturated cyclic hydrocarbon group in which one or more (preferably 1, 2, 3 or 4) ring atoms are ring heteroatoms selected from N, O or S, which may be a monovalent group or a group more than divalent, and includes monocyclic heterocyclyl groups including spirocyclic heterocyclyl groups, fused ring heterocyclyl groups and bridged heterocyclyl groups, said "spirocyclic heterocyclyl groups" means polycyclic heterocyclyl groups in which one ring atom (referred to as spiro atom) is shared between monocyclic rings, said "fused ring cycloalkyl" means polycyclic heterocyclyl groups in which each ring in a group shares an adjacent pair of ring atoms with other rings, and said "bridged cycloalkyl" means polycyclic heterocyclyl groups in which any two rings share two ring atoms which are not directly connected. Heterocyclyl also includes the case where ring atom C, S is oxo, such as ring atom C, S is substituted with C (═ O), S (═ O)2And (4) replacing. In the present invention, "3-8 membered heterocyclic group" means a heterocyclic group comprising 3 to 8 ring atoms, preferably containing 1, 2 or 3 ring heteroatoms selected from N, O or S, and specific 3-8 membered heterocyclic groups include, but are not limited to, aziridinyl, oxetanyl, azetidinyl, thietanyl, tetrahydrofuranyl, tetrahydropyrrolyl, pyrrolidinonyl, tetrahydrothienyl, imidazolidinyl, pyrazolidinyl, 1, 2-oxazolidinyl, 1, 3-oxazolidinyl, 1, 2-thiazolidinyl, 1, 3-thiazolidinyl, tetrahydro-2H-pyranyl, tetrahydro-2H-thiopyranyl, piperidinyl, piperidinonyl, piperazinyl, morpholinyl, 1, 4-dioxanyl, 1, 4-oxathianyl, piperidinonyl, piperazinyl, morpholinyl, 1, 4-oxathianyl, thianyl, and the like, 4, 5-dihydroisoxazolyl, 4, 5-dihydrooxazolyl, 2, 3-dihydrooxazolyl, 3, 4-dihydro-2H-pyrrolyl, 2, 3-dihydro-1H-pyrrolyl, 2, 5-dihydro-1H-imidazolyl, 4, 5-dihydro-1H-pyrazolyl, 4, 5-dihydro-3H-pyrazolyl, 4, 5-dihydrothiazolyl, 2H-pyranyl, 4H-pyranyl, 2H-thiopyranyl, 4H-thiopyranyl, 2, 3, 4, 5-tetrahydropyridinyl, 1, 2-Isooxazinyl, 1, 4-isooxazinyl, or 6H-1, 3-oxazinyl, and the like, with preference given to And the like. In the present invention, "3-6 membered heterocyclic group" means a heterocyclic group comprising 3 to 6 ring atoms, preferably containing 1, 2 or 3 ring heteroatoms selected from N, O or S, and specific 3-6 membered heterocyclic groups include, but are not limited to, aziridinyl, oxetanyl, azetidinyl, thietanyl, tetrahydrofuranyl, tetrahydropyrrolyl, pyrrolidinonyl, tetrahydrothienyl, imidazolidinyl, pyrazolidinyl, 1, 2-oxazolidinyl, 1, 3-oxazolidinyl, 1, 2-thiazolidinyl, 1, 3-thiazolidinyl, tetrahydro-2H-pyranyl, tetrahydro-2H-thiopyranyl, piperidinyl, piperidinonyl, piperazinyl, morpholinyl, 1, 4-dioxanyl, 1, 4-oxathianyl, piperidinonyl, piperazinyl, morpholinyl, 1, 4-oxathianyl, thianyl, and the like, 4, 5-dihydroisoxazolyl, 4, 5-dihydrooxazolyl, 2, 3-dihydrooxazolyl, 3, 4-dihydro-2H-pyrrolyl, 2, 3-dihydro-1H-pyrrolyl, 2, 5-dihydro-1H-imidazolyl, 4, 5-dihydro-1H-pyrazolyl, 4, 5-dihydro-3H-pyrazolyl, 4, 5-dihydrothiazolyl, 2H-pyranyl, 4H-pyranyl, 2H-thiopyranyl, 4H-thiopyranyl, 2, 3, 4, 5-tetrahydropyridinyl, 1, 2-isoxazolyl, 2, 5-dihydrooxazolyl, 2, 3-dihydrooxazolyl, 2-dihydrooxazolyl, 4, 5-dihydropyranyl, 4, 5-thiazolyl, 2H-thiapyranyl, 4, 5-tetrahydropyridinyl, 1, 2-isoxazolyl, 2, 5-thiazolyl, 2-thiapyranyl, 2, and a, 1, 4-isoxazolyl or 6H-1, 3-oxazinyl, etc., preferably And the like.
In the present invention, "aryl" means a cyclic hydrocarbon group having aromaticity, which may be a monovalent group or a group of two or more valences, and includes monocyclic aryl groups and condensed ring aryl groups, and "condensed ring aryl" means an aryl group containing a plurality of rings (preferably 2 or 3 rings) in which each ring of the group shares an adjacent pair of ring carbon atoms with other rings. In the present invention, "6-10 membered aryl" means an aryl group comprising 6 to 10 ring carbon atoms, including phenyl, naphthyl.
In the present invention, "heteroaryl" means a cyclic hydrocarbon group having aromaticity in which one or more (preferably 1 to 5, more preferably 1, 2, 3 or 4) ring atoms are ring heteroatoms selected from N, O or S, which may be a monovalent group or a group of more than two valences, including monocyclic heteroaryl and fused ring heteroaryl, and "fused ring heteroaryl" means a heteroaryl group containing a plurality of rings (preferably 2 or 3 rings) in which each ring of the group shares an adjacent pair of ring atoms with other rings. In the present invention, "5-12 membered heteroaryl" means a heteroaryl group comprising 5 to 12 ring atoms, preferably containing 1, 2, 3 or 4 ring heteroatoms selected from N, O or S, and specifically, 5-12 membered heteroaryl includes, but is not limited to, furyl, imidazolyl, isoxazolyl, thiazolyl, isothiazolyl, oxadiazolyl, oxazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, pyrazolyl, pyrrolyl, tetrazolyl, thiadiazolyl, thienyl, triazolyl, triazinyl, benzimidazolyl, benzofuranyl, benzothienyl, benzooxadiazolyl, benzothiadiazolyl, benzothiazolyl, furopyridyl, indazolyl, indolyl, isoindolyl, isoquinolyl, purinyl, quinolyl, quinoxalyl, thienopyridyl, and the like, preferably And the like. In the present invention, "5-6 membered heteroaryl" means a heteroaryl group comprising 5 to 6 ring atoms, preferably containing 1, 2, 3 or4 ring heteroatoms selected from N, O or S, specific, 5-6 membered heteroaryl groups include, but are not limited to, furyl, imidazolyl, isoxazolyl, thiazolyl, isothiazolyl, oxadiazolyl, oxazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, pyrazolyl, pyrrolyl, tetrazolyl, thiadiazolyl, thienyl, triazolyl, triazinyl and the like, preferably And the like.
In the present invention, "-C (═ O) -C1-4Alkyl "means" C "as defined above1-4Alkyl "is a group formed by the attachment of-C (═ O) -; "-SO2-C1-4Alkyl "means" C "as defined above1-4Alkyl "and-SO2-linking the formed groups.
In the present invention, the term "one or more" means that the number of the substituents may be the number of all chemically substitutable positions of the substituent, preferably 1 to 6, more preferably 1 to 5, more preferably 1 to 3, more preferably 1 to 2, and still more preferably 1.
In the present invention, the "amino protecting group" refers to a chemical group that is attached to an amino group and is easily removed under certain conditions, and includes, but is not limited to, alkoxycarbonyl groups, acyl groups, alkyl groups; for example, t-butoxycarbonyl, benzyloxycarbonyl, fluorenylmethyloxycarbonyl, allyloxycarbonyl, phthaloyl, benzyl, p-methoxybenzyl, trityl and the like. Those skilled in the art can refer to the textbook Greene's Protective Groups in Organic Synthesis (4)thedition) to make appropriate selections and operations.
The pharmaceutical compositions of the present invention may be prepared by methods well known in the art, such as conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, and lyophilizing processes. The pharmaceutical compositions of the present invention may be administered to a subject by any convenient route of administration, including, but not limited to, oral, rectal, parenteral (e.g., injection, including subcutaneous, intradermal, intramuscular, intravenous, etc.), topical (including, for example, transdermal, intranasal, ocular, buccal, and sublingual), pulmonary (e.g., oral or nasal inhalation or insufflation therapy using an aerosol), and the like.
Solid dosage forms suitable for oral administration include tablets, pills, capsules, powders, granules and the like. In preparing these solid dosage forms, one or more of excipients, fillers or compatibilizers, binders, disintegrants, stabilizers, wetting agents, adsorbents, lubricants, or encapsulating materials conventionally employed in the art may be added in addition to the compound of the present invention or a pharmaceutically acceptable salt thereof.
Liquid dosage forms suitable for oral administration include solutions, suspensions, emulsions, syrups or tinctures and the like. In addition to the compounds of the present invention or pharmaceutically acceptable salts thereof, the liquid dosage forms may contain one or more of diluents, solubilizers, emulsifiers, wetting agents, suspending agents, sweeteners, flavorants, aromas, or preservatives conventionally employed in the art.
Dosage forms suitable for topical administration include ointments, powders, patches, drops, sprays, inhalants and the like, and the compound of the present invention or a pharmaceutically acceptable salt thereof as an active ingredient is mixed together with a pharmaceutically acceptable carrier under sterile conditions.
Dosage forms suitable for rectal administration include suppositories comprising a compound of the present invention or a pharmaceutically acceptable salt thereof and a suitable base.
Dosage forms suitable for parenteral injection include sterile physiologically acceptable aqueous or anhydrous solutions, dispersions, suspensions or emulsions, and sterile powders for reconstitution into sterile injectable solutions or dispersions.
The pharmaceutical preparation is preferably in unit dosage form. In this form, the preparation is subdivided into unit doses containing appropriate quantities of the active component. The unit dosage forms can be packaged in packages containing discrete quantities of the agent, such as packaged tablets, capsules.
In treating a patient, an effective amount of a compound of the present invention or a pharmaceutically acceptable salt thereof or a pharmaceutical composition thereof is administered to a patient (e.g., a human) in need of treatment. In some embodiments, a therapeutically effective amount of a compound of the present invention, or a pharmaceutically acceptable salt thereof, is about 0.01 to 1000 mg/day, preferably about 0.1 to 500 mg/day. The precise dosage will depend upon, among other things, the route of administration, the form of the compound when administered, the health of the subject (patient) to be treated, and the experience of the attending physician.
The compounds of the present invention or pharmaceutically acceptable salts thereof or pharmaceutical compositions thereof may also be administered in combination with other antineoplastic agents, such as chemotherapeutic agents, or in combination with other therapies, such as radiation therapy or surgery, as a pre-or post-operative adjuvant.
The abbreviations used in the present invention have the following meanings:
boc: tert-butyloxycarbonyl radical
Cbz: benzyloxycarbonyl group
Bn: benzyl radical
Pd(dPPi)Cl2: [1, 1' -bis (diphenylphosphino) ferrocene]Palladium dichloride
Pd2(dba)3: tris (dibenzylideneacetone) dipalladium
Xantphos: 4, 5-bis-diphenylphosphino-9, 9-dimethylxanthene
Brettphos: dicyclohexyl [3, 6-dimethoxy-2 ', 4', 6 '-triisopropyl [1, 1' -biphenyl ] -2-yl ] phosphine
PtO2: platinum dioxide
Pd(PPh3)4: tetrakis (triphenylphosphine) palladium
PdCl2: palladium dichloride
Pd(OH)2: palladium hydroxide
Pd(OAc)2: palladium acetate
Pd: palladium (II)
HCl: hydrogen chloride
HBr: hydrogen bromide
NaBH(OAc)3: sodium triacetoxyborohydride
NaBH4: sodium borohydride
NaBH3CN: sodium cyanoborohydride
DCM: methylene dichloride
MeOH: methanol
EA: ethyl acetate
CDCl3: deuterated chloroform
DMSO, DMSO: dimethyl sulfoxide
TLC: thin layer chromatography
Description of the drawings:
FIG. 1 is a plot of the tumor volume change of subcutaneously transplanted tumors of transfected-cell Ba/F3 KIF5B-RET nude mice with the compound of example 12 and LOXO-292 at a dose of 10mg/kg twice daily.
FIG. 2 is a plot of the change in tumor volume of subcutaneous transplantable tumors of the compound of example 12 and LOXO-292 in nude mice at a dose of 30mg/kg twice daily, of stably transfected cells Ba/F3 KIF 5B-RET-G810R.
Detailed Description
The embodiments of the present invention will be explained below with reference to specific examples. It should be understood that these examples are for illustrative purposes only and are not intended to limit the scope of the present invention. The following examples do not specify particular techniques or conditions, according to techniques or conditions described in the literature in the field or according to the product specifications. The reagents or instruments used are not indicated by the manufacturer, and are all conventional products commercially available.
I. Preparation examples of Compounds of the present invention
The structure of the compounds of the invention is determined by Nuclear Magnetic Resonance (NMR) or/and liquid mass chromatography (LC-MS). NMR chemical shifts (δ) are given in parts per million (ppm). NMR was measured using a Bruker AVANCE-400 NMR spectrometer using deuterated dimethyl sulfoxide (DMSO-d)6) And deuterated chloroform (CDCl)3) Internal standard is Tetramethylsilane (TMS).
The LC-MS was measured by Agilent 6410 Triple Quad LC/MS.
The thin layer chromatography silica gel plate is prepared from HSGF254 of tobacco yellow sea or GF254 of Qingdao, TLC is 0.15-0.20 mm, and the thin layer chromatography separation and purification product is 0.4-0.5 mm. The column chromatography generally uses 200-mesh and 300-mesh silica gel of the Tibet yellow sea silica gel as a carrier.
Example 1: 6- (2, 2-difluoroethylamine) -4- (6- (6- ((6-methoxypyridin-3-yl) methyl) -3, 6-diazabicyclo [3.1.1] heptan-3-yl) pyridin-3-yl) pyrazolo [1,5-a ] pyridine-3-carbonitrile
Step 1: 6-bromo-4- (6-fluoropyridin-3-yl) pyrazolo [1,5-a ] pyridine-3-carbonitrile
To a 500ml three-necked flask were added 4, 6-dibromopyrazolo [1,5-a ] pyridine-3-carbonitrile (33.0g, 0.11mol), 2-fluoro-5-pyridineboronic acid (14.1g, 0.10mmol), [1, 1' -bis (diphenylphosphino) ferrocene ] dichloropalladium (2.7g, 3.70mmol), potassium fluoride dihydrate (31.0g, 0.33 mmol) and 150ml of N, N-dimethylformamide, and reacted under argon at 60 ℃ overnight. After the reaction was completed, the reaction mixture was cooled to room temperature, and 500ml of water was added thereto. Filtering the reaction solution, and leaching a filter cake with acetonitrile and ethyl acetate. Vacuum drying to obtain 30g of 6-bromo-4- (6-fluoropyridin-3-yl) pyrazolo [1,5-a ] pyridine-3-carbonitrile. The yield thereof was found to be 86%.
1H NMR(400MHz,DMSO-d6)δ9.48(d,J=1.6Hz,1H),8.73(s,1H), 8.51(d,J=2.5Hz,1H),8.27(td,J=8.1,2.6Hz,1H),7.86(d,J=1.6Hz, 1H),7.40(dd,J=8.4,2.8Hz,1H).
Step 2: 3- (5- (6-bromo-3-cyanopyrazole [1,5-a ] pyridin-4-yl) pyridin-2-yl) -3, 6-diazabicyclo [3.1.1] heptane-6-carbamic acid tert-butyl ester
6-bromo-4- (6-fluoropyridin-3-yl) pyrazolo [1,5-a ] pyridine-3-carbonitrile (4.35g, 13.7mmol), 6- (tert-butoxycarbonyl) -3, 6-diazabicyclo [3.1.1] heptane (3.25g, 16.3mmol), potassium carbonate (5.67g, 41.1mmol) and 60ml of dimethyl sulfoxide were added to a 250ml three-necked flask and reacted at 100 ℃ overnight. After the reaction was completed, the reaction mixture was cooled to room temperature, and 200ml of water was added thereto. The reaction mixture was filtered, and the filter cake was dissolved in a mixed solvent (DCM: MeOH: 10: 1) and then dried by suction, acetonitrile was taken with water three times, and silica gel column chromatography was carried out to give 3.4g of tert-butyl 3- (5- (6-bromo-3-cyanopyrazole [1,5-a ] pyridin-4-yl) pyridin-2-yl) -3, 6-diazabicyclo [3.1.1] heptane-6-carbamate. The yield thereof was found to be 50%.
MS m/z:495.1/497.1[M+1]+。
1H NMR(400MHz,CDCl3)δ8.68(d,J=1.3Hz,1H),8.36(d,J=2.1 Hz,1H),8.25(s,1H),7.72(dd,J=8.8,2.3Hz,1H),7.39(d,J=1.3Hz, 1H),6.66(d,J=8.8Hz,1H),4.31(d,J=4.3Hz,2H),4.15(s,2H),3.55(s, 2H),2.68(d,J=7.6Hz,1H),1.53(d,J=8.7Hz,1H),1.37(d,J=5.2Hz, 9H).
And step 3: 4- (6- (3, 6-diazabicyclo [3.1.1] heptan-3-yl) pyridin-3-yl) -6-bromopyrazolo [1,5-a ] pyridine-3-carbonitrile
To a 250ml three-necked flask were added tert-butyl 3- (5- (6-bromo-3-cyanopyrazole [1,5-a ] pyridin-4-yl) pyridin-2-yl) -3, 6-diazabicyclo [3.1.1] heptane-6-carbamate (3.4g, 6.88mmol) and 50ml of a 4.0M solution of hydrogen chloride in methanol, and reacted at 25 ℃ overnight. And the MS monitors the completion of the reaction. The reaction solution was drained and acetonitrile was taken with water three times to obtain 3.66g of crude 4- (6- (3, 6-diazabicyclo [3.1.1] heptan-3-yl) pyridin-3-yl) -6-bromopyrazolo [1,5-a ] pyridine-3-carbonitrile. The yield thereof was found to be 99%.
MS m/z:395.0/397.0[M+1]+。
And 4, step 4: 6-bromo-4- (6- (6- ((6-methoxypyridin-3-yl) methyl) -3, 6-diazabicyclo [3.1.1] heptan-3-yl) pyridin-3-yl) pyrazolo [1,5-a ] pyridine-3-carbonitrile
To a 250ml three-necked flask was added crude 4- (6- (3, 6-diazabicyclo [3.1.1] heptan-3-yl) pyridin-3-yl) -6-bromopyrazolo [1,5-a ] pyridine-3-carbonitrile (3.66g, 6.88mmol), 6-methoxy-3-pyridinecarboxaldehyde (1.88g, 13.76mmol) and 100ml dichloroethane, sodium triacetoxyborohydride (7.3g, 34.4mmol) was slowly added, reacted at room temperature overnight, and TLC monitored for completion of the reaction. Quenching reaction by saturated sodium bicarbonate, washing with water, extracting by dichloromethane, drying an organic phase, draining, and carrying out silica gel column chromatography to obtain 2.8g of 6-bromo-4- (6- (6- ((6-methoxypyridin-3-yl) methyl) -3, 6-diazabicyclo [3.1.1] heptan-3-yl) pyridin-3-yl) pyrazolo [1,5-a ] pyridine-3-carbonitrile. The yield thereof was found to be 79%.
MS m/z:516.1/518.1[M+1]+。
1H NMR(400MHz,CDCl3)δ8.70(d,J=1.5Hz,1H),8.40(d,J=2.2 Hz,1H),8.26(s,1H),8.11(d,J=2.0Hz,1H),7.77(dd,J=8.8,2.5Hz, 2H),7.40(d,J=1.5Hz,1H),6.71(dd,J=15.8,8.7Hz,2H),3.90(d,J= 12.7Hz,7H),3.68(d,J=9.2Hz,4H),2.84(s,1H),1.71(d,J=9.0Hz, 1H).
And 5: 6- (2, 2-difluoroethylamine) -4- (6- (6- ((6-methoxypyridin-3-yl) methyl) -3, 6-diazabicyclo [3.1.1] heptan-3-yl) pyridin-3-yl) pyrazolo [1,5-a ] pyridine-3-carbonitrile
To a 50ml single neck flask was added 6-bromo-4- (6- (6- ((6-methoxypyridin-3-yl) methyl) -3, 6-diazabicyclo [3.1.1] heptan-3-yl) pyridin-3-yl) pyrazolo [1,5-a ] pyridine-3-carbonitrile (103 mg, 0.20mmol), tris (dibenzylideneacetone) dipalladium (18.3mg, 0.02mmol), dicyclohexyl [3, 6-dimethoxy-2 ', 4', 6 '-triisopropyl [1, 1' -biphenyl ] -2-yl ] phosphine (10.8mg, 0.02mmol), cesium carbonate (163mg, 0.50mmol), 2, 2-difluoroethylamine (33mg, 0.40mmol) and 10ml dioxane, under argon, and reacted overnight at 90 ℃. Kieselguhr for filtration assistance, evaporation of the filtrate under reduced pressure and chromatography on silica gel (dichloromethane: methanol 15: 1) to give 77mg of the product 6- (2, 2-difluoroethylamine) -4- (6- (6- ((6-methoxypyridin-3-yl) methyl) -3, 6-diazabicyclo [3.1.1] heptan-3-yl) pyridin-3-yl) pyrazolo [1,5-a ] pyridine-3-carbonitrile. The yield thereof was found to be 74%.
MS m/z:517.2[M+1]+。
1H NMR(400MHz,DMSO-d6)δ8.44(s,1H),8.36(s,1H),8.25 (s,1H),8.08(s,1H),7.80(d,J=8.0Hz,1H),7.69(d,J=8.0Hz, 1H),7.15(s,1H),6.79(t,J=8.0Hz,2H),6.32(t,J=8.0Hz,1H), 6.22(tt,J1=56.0Hz,J2=4.0Hz,1H),3.83(s,3H),3.79-3.61(m, 4H),3.59-3.46(m,4H),3.39-3.28(m,2H),2.50(s,1H),1.60(d,J= 8.0Hz,1H)。
Example 2: 6- (ethylamine) -4- (6- (6- ((6-methoxypyridin-3-yl) methyl) -3, 6-diazabicyclo [3.1.1] heptan-3-yl) pyridin-3-yl) pyrazolo [1,5-a ] pyridine-3-carbonitrile
The compound was synthesized as in example 1. And taking the intermediate 2A and ethylamine as raw materials to obtain a target compound 6- (ethylamine) -4- (6- (6- ((6-methoxypyridine-3-yl) methyl) -3, 6-diazabicyclo [3.1.1] heptane-3-yl) pyridine-3-yl) pyrazole [1,5-a ] pyridine-3-carbonitrile. The yield thereof was found to be 30%.
MS m/z:481.5[M+1]+。
1H NMR(400MHz,DMSO-d6)δ8.39(s,1H),8.34(s,1H),8.09(s,1H), 7.93(s,1H),7.78(d,J=8.7Hz,1H),7.71(s,1H),7.07(s,1H),6.90-6.67 (m,2H),6.01(s,1H),3.82(s,3H),3.72(s,4H),3.53(s,4H),3.14-2.98(m, 2H),2.07(s,1H),1.59(s,1H),1.22(t,J=6.9Hz,3H).
Example 3: 4- (6- (6- ((6-methoxypyridin-3-yl) methyl) -3, 6-diazabicyclo [3.1.1] heptan-3-yl) pyridin-3-yl) -6- (n-propylamine) pyrazolo [1,5-a ] pyridine-3-carbonitrile
The compound was synthesized as in example 1. The intermediate 2A and n-propylamine are used as raw materials to obtain a target compound 4- (6- (6- ((6-methoxypyridin-3-yl) methyl) -3, 6-diazabicyclo [3.1.1] heptane-3-yl) pyridine-3-yl) -6- (n-propylamine) pyrazole [1,5-a ] pyridine-3-carbonitrile. The yield thereof was found to be 13%.
MS m/z:495.3[M+1]+。
1H NMR(400MHz,DMSO-d6)δ8.40(s,1H),8.35(d,J=2.0Hz, 1H),8.09(s,1H),7.95(d,J=2.0Hz,1H),7.80(d,J=8.0Hz,1H), 7.70(d,J=8.0Hz,1H),7.07(d,J=2.0Hz,1H),6.85-6.74(m,2H), 5.98(t,J=8.0Hz,1H),3.83(s,3H),3.80-3.63(m,4H),3.62-3.45 (m,4H),3.10-2.98(m,2H),2.50(s,1H),1.68-1.54(m,3H),0.99(t, J=6.0Hz,3H)。
Example 4: 4- (6- (6- ((6-methoxypyridin-3-yl) methyl) -3, 6-diazabicyclo [3.1.1] heptan-3-yl) pyridin-3-yl) -6- (2, 2, 2-trifluoroethylamine) pyrazolo [1,5-a ] pyridine-3-carbonitrile
The compound was synthesized as in example 1. The intermediate 2A and trifluoroethylamine are used as raw materials to obtain a target compound 4- (6- (6- ((6-methoxypyridin-3-yl) methyl) -3, 6-diazabicyclo [3.1.1] heptane-3-yl) pyridine-3-yl) -6- (2, 2, 2-trifluoroethylamine) pyrazole [1,5-a ] pyridine-3-carbonitrile. The yield thereof was found to be 68%.
MS m/z:535.4[M+1]+。
1H NMR(400MHz,DMSO-d6)δ8.46(s,1H),8.37(d,J=2.0Hz, 2H),8.09(s,1H),7.81(d,J=8.0Hz,1H),7.74-7.66(m,1H),7.18 (d,J=2.0Hz,1H),6.86-6.74(m,2H),6.60(t,J=8.0Hz,1H),4.18-4.05 (m,2H),3.83(s,3H),3.80-3.63(m,4H),3.62-3.40(m,4H),2.50 (s,1H),1.60(s,1H)。
Example 5: 6- (isobutylamino) -4- (6- (6- ((6-methoxypyridin-3-yl) methyl) -3, 6-diazabicyclo [3.1.1] heptan-3-yl) pyridin-3-yl) pyrazolo [1,5-a ] pyridine-3-carbonitrile
The compound was synthesized as in example 1. And taking the intermediate 2A and isobutylamine as raw materials to obtain a target compound 6- (isobutylamino) -4- (6- (6- ((6-methoxypyridin-3-yl) methyl) -3, 6-diazabicyclo [3.1.1] heptane-3-yl) pyridin-3-yl) pyrazolo [1,5-a ] pyridine-3-carbonitrile. The yield thereof was found to be 60%.
MS m/z:509.3[M+1]+。
1H NMR(400MHz,DMSO-d6)δ8.40(s,1H),8.36(s,1H),8.09 (s,1H),7.94(s,1H),7.80(d,J=8.0Hz,1H),7.70(d,J=8.0Hz, 1H),7.11(s,1H),6.85-6.75(m,2H),6.00(t,J=8.0Hz,1H),3.83 (s,3H),3.79-3.63(m,4H),3.62-3.42(m,4H),2.89(t,J=6.0Hz, 2H),1.96-1.85(m,1H),2.50(s,1H),1.60(s,1H),0.99(t,J=6.4Hz, 6H)。
Example 6: 6- (3, 3-Difluorocyclobutylamino) -4- (6- (6- ((6-methoxypyridin-3-yl) methyl) -3, 6-diazabicyclo [3.1.1] heptan-3-yl) pyridin-3-yl) pyrazolo [1,5-a ] pyridine-3-carbonitrile
The compound was synthesized as in example 1. The intermediate 2A and the 3, 3-difluorocyclobutylamine are used as raw materials to obtain a target compound 6- (3, 3-difluorocyclobutylamine) -4- (6- (6- ((6-methoxypyridin-3-yl) methyl) -3, 6-diazabicyclo [3.1.1] heptane-3-yl) pyridine-3-yl) pyrazole [1,5-a ] pyridine-3-carbonitrile. The yield thereof was found to be 50%.
MS m/z:543.2[M+1]+。
1H NMR(400MHz,DMSO-d6)δ8.45(s,1H),8.36(d,J=1.88Hz,1H), 8.09(br.s.,1H),7.98(s,1H),7.80(d,J=7.52Hz,1H),7.70(d,J=5.91Hz, 1H),7.02(s,1H),6.73-6.86(m,2H),6.56(d,J=6.18Hz,1H),3.88-3.86 (m,1H),3.83(s,3H),3.76-3.64(m,4H),3.60-3.45(m,4H),3.17(tt, J=7.29,13.94Hz,2H),2.61-2.49(m,3H),1.60(s,1H).
Example 7: 6- (cyanomethylamino) -4- (6- (6- ((6-methoxypyridin-3-yl) methyl) -3, 6-diazabicyclo [3.1.1] heptan-3-yl) pyridin-3-yl) pyrazolo [1,5-a ] pyridine-3-carbonitrile
The compound was synthesized as in example 1. And taking the intermediate 2A and aminoacetonitrile as raw materials to obtain a target compound 6- (cyanomethylamino) -4- (6- (6- ((6-methoxypyridin-3-yl) methyl) -3, 6-diazabicyclo [3.1.1] heptane-3-yl) pyridin-3-yl) pyrazolo [1,5-a ] pyridine-3-carbonitrile. The yield thereof was found to be 15%.
MS m/z:492.2[M+1]+。
Example 8: 6- (2-hydroxyethylamine) -4- (6- (6- ((6-methoxypyridin-3-yl) methyl) -3, 6-diazabicyclo [3.1.1] heptan-3-yl) pyridin-3-yl) pyrazolo [1,5-a ] pyridine-3-carbonitrile
The compound was synthesized as in example 1. And taking the intermediate 2A and aminoethanol as raw materials to obtain a target compound 6- (2-hydroxyethylamine) -4- (6- (6- ((6-methoxypyridin-3-yl) methyl) -3, 6-diazabicyclo [3.1.1] heptane-3-yl) pyridin-3-yl) pyrazole [1,5-a ] pyridine-3-carbonitrile. The yield thereof was found to be 15%.
MS m/z:497.4[M+1]+。
1H NMR(400MHz,DMSO-d6)δ8.41(s,1H),8.35(s,1H),8.10 (s,1H),8.02(s,1H),7.80(d,J=8.0Hz,1H),7.70(d,J=8.0Hz, 1H),7.15(s,1H),6.86-6.73(m,2H),5.99(t,J=8.0Hz,1H),4.78(t, J=5.2Hz,1H),3.96-3.85(m,2H),3.83(s,3H),3.79-3.63(m,4H), 3.61-3.44(m,4H),3.30(s,2H),3.21-3.10(m,2H),2.50(s,1H),1.60 (s,1H)。
Example 9: 6- (2-hydroxy-2-methylpropylamine) -4- (6- (6- ((6-methoxypyridin-3-yl) methyl) -3, 6-diazabicyclo [3.1.1] heptan-3-yl) pyridin-3-yl) pyrazolo [1,5-a ] pyridine-3-carbonitrile
The compound was synthesized as in example 1. The intermediate 2A and 1-amino 2-methyl 2-propanol are used as raw materials to obtain the target compound 6- (2-hydroxy-2-methylpropylamine) -4- (6- (6- ((6-methoxypyridin-3-yl) methyl) -3, 6-diazabicyclo [3.1.1] heptane-3-yl) pyridin-3-yl) pyrazole [1,5-a ] pyridine-3-carbonitrile. The yield thereof was found to be 8%.
MS m/z:525.3[M+1]+。
1H NMR(400MHz,DMSO-d6)δ8.39(s,1H),8.36(s,1H),8.10(s, 1H),8.05(s,1H),7.80(d,J=8.0Hz,1H),7.70(d,J=8.0Hz,1H),7.26 (s,1H),6.84-6.74(m,2H),5.83(t,J=8.0Hz,1H),4.56(s,1H),3.82 (s,3H),3.78-3.66(m,4H),3.59-3.42(m,4H),3.00(d,J=6.0Hz,2H), 2.50(s,1H),1.60(s,1H),1.21(s,6H)。
Example 10: 6- ((3-fluoroazetidin-3-yl) methylamino) -4- (6- (6- ((6-methoxypyridin-3-yl) methyl) -3, 6-diazabicyclo [3.1.1] heptan-3-yl) pyridin-3-yl) pyrazolo [1,5-a ] pyridine-3-carbonitrile
Step 1: 3- ((3-cyano-4- (6- (6- ((6-methoxypyridin-3-yl) methyl) -3, 6-diazabicyclo [3.1.1] heptan-3-yl) pyridin-3-yl) pyrazolo [1,5-a ] pyridin-6-ylamino) methyl) -3-fluoroazetidine-1-carboxylic acid tert-butyl ester
The compound was synthesized as in example 1. Using the intermediate 2A and 3- (aminomethyl) -3-fluoroazetidine-1-carboxylic acid tert-butyl ester as raw materials to obtain a target compound, namely 3- ((3-cyano-4- (6- (6- ((6-methoxypyridin-3-yl) methyl) -3, 6-diazabicyclo [3.1.1] heptan-3-yl) pyridin-3-yl) pyrazolo [1,5-a ] pyridin-6-ylamino) methyl) -3-fluoroazetidine-1-carboxylic acid tert-butyl ester. The yield thereof was found to be 74%.
MS m/z:640.2[M+1]+。
Step 2: 6- ((3-fluoroazetidin-3-yl) methylamino) -4- (6- (6- ((6-methoxypyridin-3-yl) methyl) -3, 6-diazabicyclo [3.1.1] heptan-3-yl) pyridin-3-yl) pyrazolo [1,5-a ] pyridine-3-carbonitrile
To a 25ml single neck flask was added tert-butyl 3- ((3-cyano-4- (6- (6- ((6-methoxypyridin-3-yl) methyl) -3, 6-diazabicyclo [3.1.1] heptan-3-yl) pyridin-3-yl) pyrazolo [1,5-a ] pyridin-6-ylamino) methyl) -3-fluoroazetidine-1-carboxylate (95mg, 0.15mmol), 4ml dichloromethane and 4ml trifluoroacetic acid for 2 hours under argon. The reaction solution was evaporated to dryness under reduced pressure, 20ml of dichloromethane and 10ml of saturated sodium bicarbonate were added, stirred until no air bubbles were present and the organic layer was separated, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. Column chromatography on silica gel (dichloromethane: methanol ═ 15: 1) gives 36mg of the product 6- ((3-fluoroazetidin-3-yl) methylamino) -4- (6- (6- ((6-methoxypyridin-3-yl) methyl) -3, 6-diazabicyclo [3.1.1] heptan-3-yl) pyridin-3-yl) pyrazolo [1,5-a ] pyridine-3-carbonitrile. The yield thereof was found to be 44%.
MS m/z:540.2[M+1]+。
1H NMR(400MHz,DMSO-d6)δ8.43(s,1H),8.35(d,J=2.2Hz,1H), 8.26(s,1H),8.14(s,1H),7.79(dd,J=8.8,2.4Hz,1H),7.74(dd,J=5.5, 3.5Hz,1H),7.20(s,1H),6.83-6.75(m,2H),6.53(t,J=5.9Hz,1H),4.18 (d,J=2.6Hz,1H),4.13(s,1H),3.83(s,3H),3.82-3.79(m,4H),3.76- 3.73(m,4H),3.64-3.60(m,5H),2.64(d,J=18.9Hz,1H),1.65(s,1H).
Example 11: 4- (6- (6- (3-fluoro-4-methoxybenzyl) -3, 6-diazabicyclo [3.1.1] heptan-3-yl) pyridin-3-yl) -6- ((3-fluoroazetidin-3-yl) methylamino) pyrazolo [1,5-a ] pyridine-3-carbonitrile
Step 1: 4- (6- (6- (3-fluoro-4-methoxybenzyl) -3, 6-diazabicyclo [3.1.1] heptan-3-yl) pyridin-3-yl) -6-bromopyrazolo [1,5-a ] pyridine-3-carbonitrile
The compound is synthesized with the intermediate 2A. And (3) after the protecting group of the intermediate 1 is removed, carrying out reductive amination with 3-fluoro-4-methoxybenzaldehyde to obtain an intermediate 2B. The yield thereof was found to be 44%.
MS m/z:533.0[M+1]+。
1H NMR(400MHz,CDCl3)δ8.69(d,J=1.5Hz,1H),8.40(d,J=2.1 Hz,1H),8.27(s,1H),7.76(dd,J=8.8,2.5Hz,1H),7.40(d,J=1.5Hz, 1H),7.15(dd,J=12.2,1.7Hz,1H),7.06(d,J=8.4Hz,1H),6.89(t,J=8.5 Hz,1H),6.69(d,J=8.8Hz,1H),3.87(s,3H),3.83(d,J=6.1Hz,4H), 3.59(d,J=8.8Hz,4H),2.74(d,J=6.9Hz,1H),1.66(d,J=8.7Hz,1H).
Step 2: 3- ((4- (6- (6- (3-fluoro-4-methoxybenzyl) -3, 6-diazabicyclo [3.1.1] heptan-3-yl) pyridin-3-yl) -3-cyanopyrazole [1,5-a ] pyridin-6-ylamino) methyl) -3-fluoroazetidine-1-carboxylic acid tert-butyl ester
The compound was synthesized as in step 1 of example 10. The yield thereof was found to be 34%.
MS m/z:657.3[M+1]+。
And step 3: 4- (6- (6- (3-fluoro-4-methoxybenzyl) -3, 6-diazabicyclo [3.1.1] heptan-3-yl) pyridin-3-yl) -6- ((3-fluoroazetidin-3-yl) methylamino) pyrazolo [1,5-a ] pyridine-3-carbonitrile
The compound was synthesized as in step 2 of example 10. The yield thereof was found to be 30%.
MS m/z:557.0[M+1]+。
1H NMR(400MHz,DMSO-d6)δ8.43(s,1H),8.35(d,J=2.2Hz,1H), 8.26(d,J=1.2Hz,1H),7.79(dd,J=8.8,2.3Hz,1H),7.25-7.05(m,4H), 6.78(d,J=8.8Hz,1H),6.53(t,J=6.2Hz,1H),4.17-4.12(m,1H),4.11 (s,1H),3.81(s,3H),3.78-3.70(m,6H),3.65-3.48(m,6H),2.60(s,1H), 1.62(d,J=7.8Hz,1H).
Example 12: 6- (2-fluoroethylamine) -4- (6- (6- ((6-methoxypyridin-3-yl) methyl) -3, 6-diazabicyclo [3.1.1] heptan-3-yl) pyridin-3-yl) pyrazolo [1,5-a ] pyridine-3-carbonitrile
Step 1: 3-cyano-4- (6- (6- ((6-methoxypyridin-3-yl) methyl) -3, 6-diazabicyclo [3.1.1] heptan-3-yl) pyridin-3-yl) pyrazolo [1,5-a ] pyridin-6-ylcarbamic acid tert-butyl ester
The compound was synthesized as in step 5 of example 1. The intermediate 2A and the tert-butyl carbamate are taken as raw materials for synthesis. The yield thereof was found to be 68%.
MS m/z:553.4[M+1]+。
Step 2: 3-cyano-4- (6- (6- ((6-methoxypyridin-3-yl) methyl) -3, 6-diazabicyclo [3.1.1] heptan-3-yl) pyridin-3-yl) pyrazolo [1,5-a ] pyridin-6-yl (2-fluoroethyl) carbamic acid tert-butyl ester
To a 25ml single-neck flask was added tert-butyl 3-cyano-4- (6- (6- ((6-methoxypyridin-3-yl) methyl) -3, 6-diazabicyclo [3.1.1] heptan-3-yl) pyridin-3-yl) pyrazolo [1,5-a ] pyridin-6-ylcarbamate (55mg, 0.10mmol), cesium carbonate (66mg, 0.20mmol), 1-fluoro-2-iodoethane (35mg, 0.20mmol) and 5ml of DMF, and reacted at 80 ℃ for 4 hours under nitrogen. The reaction mixture was quenched by the addition of 15ml of water and extracted three times with ethyl acetate (15 ml). The organic layer was evaporated to dryness under reduced pressure and crude silica gel column chromatography (dichloromethane: methanol ═ 30: 1) afforded 60mg of the product tert-butyl 3-cyano-4- (6- (6- ((6-methoxypyridin-3-yl) methyl) -3, 6-diazabicyclo [3.1.1] heptan-3-yl) pyridin-3-yl) pyrazolo [1,5-a ] pyridin-6-yl (2-fluoroethyl) carbamate. The yield thereof was found to be 99%.
MS m/z:599.5[M+1]+。
And step 3: 6- (2-fluoroethylamine) -4- (6- (6- ((6-methoxypyridin-3-yl) methyl) -3, 6-diazabicyclo [3.1.1] heptan-3-yl) pyridin-3-yl) pyrazolo [1,5-a ] pyridine-3-carbonitrile
To a 10ml single-neck flask were added tert-butyl 3-cyano-4- (6- (6- ((6-methoxypyridin-3-yl) methyl) -3, 6-diazabicyclo [3.1.1] heptan-3-yl) pyridin-3-yl) pyrazolo [1,5-a ] pyridin-6-yl (2-fluoroethyl) carbamate (60mg, 0.10mmol) and 5ml of a 4.0M solution of hydrogen chloride in methanol under argon and reacted at 25 ℃ for 2 hours. The reaction solution was evaporated to dryness under reduced pressure, 20ml of dichloromethane and 10ml of saturated sodium bicarbonate were added, stirred until no air bubbles were present and the organic layer was separated, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. Column chromatography on silica gel (dichloromethane: methanol ═ 15: 1) gives 20mg of the product 6- (2-fluoroethylamine) -4- (6- (6- ((6-methoxypyridin-3-yl) methyl) -3, 6-diazabicyclo [3.1.1] heptan-3-yl) pyridin-3-yl) pyrazolo [1,5-a ] pyridine-3-carbonitrile. The yield thereof was found to be 40%.
MS m/z:499.3[M+1]+。
1H NMR(400MHz,DMSO-d6)δ8.41(s,1H),8.35(d,J=1.6Hz,1H), 8.11(d,J=1.4Hz,2H),7.79(d,J=7.5Hz,1H),7.70(s,1H),7.12(s,1H), 6.80(d,J=8.5Hz,2H),6.25(t,J=5.8Hz,1H),4.62(dt,J=47.8,4.7Hz, 2H),3.83(s,3H),3.80-3.61(m,4H),3.60-3.50(m,4H),3.43(ddd,J= 14.5,11.1,5.9Hz,2H),2.50(s,1H),1.62(s,1H).
Example 13: 4- (6- (6- (3-fluoro-4-methoxybenzyl) -3, 6-diazabicyclo [3.1.1] heptan-3-yl) pyridin-3-yl) -6- (2-fluoroethylamino) pyrazolo [1,5-a ] pyridine-3-carbonitrile
Step 1: 3-cyano-4- (6- (6- ((3-fluoro-4-methoxybenzyl) -3, 6-diazabicyclo [3.1.1] heptan-3-yl) pyridin-3-yl) pyrazolo [1,5-a ] pyridin-6-ylcarbamic acid tert-butyl ester
The compound was synthesized as in step 5 of example 1. The intermediate 2B and the tert-butyl carbamate are taken as raw materials for synthesis.
MS m/z:570.2[M+1]+。
Step 2: 3-carbonitrile-4- (6- (6- ((3-fluoro-4-methoxybenzyl) -3, 6-diazabicyclo [3.1.1] heptan-3-yl) pyridin-3-yl) pyrazolo [1,5-a ] pyridin-6-yl (2-fluoroethyl) carbamic acid tert-butyl ester
The compound was synthesized as in step 2 of example 12.
MS m/z:616.2[M+1]+。
And step 3: 4- (6- (6- (3-fluoro-4-methoxybenzyl) -3, 6-diazabicyclo [3.1.1] heptan-3-yl) pyridin-3-yl) -6- (2-fluoroethylamino) pyrazolo [1,5-a ] pyridine-3-carbonitrile
This compound was synthesized as described for 6- (2-fluoroethylamine) -4- (6- (6- ((6-methoxypyridin-3-yl) methyl) -3, 6-diazabicyclo [3.1.1] heptan-3-yl) pyridin-3-yl) pyrazolo [1,5-a ] pyridine-3-carbonitrile. The yield thereof was found to be 28%.
MS m/z:516.2[M+1]+。
1H NMR(400MHz,DMSO-d6)δ8.42(s,1H),8.35(d,J=1.5Hz,1H), 8.11(d,J=1.5Hz,1H),7.88-7.64(m,2H),7.13(d,J=1.7Hz,2H),6.80 (d,J=8.8Hz,1H),6.27(t,J=5.9Hz,1H),4.63(dt,J=47.8,4.8Hz,2H), 3.83(s,3H),3.78-3.66(m,4H),3.63-3.50(m,4H),3.44(ddd,J=28.5, 10.1,5.1Hz,2H),2.64-2.54(m,1H),1.63(s,1H)。
Example 14: 4- (6- (6- (2-fluoro-5-methoxybenzyl) -3, 6-diazabicyclo [3.1.1] heptan-3-yl) pyridin-3-yl) -6- (2, 2-difluoroethylamino) pyrazolo [1,5-a ] pyridine-3-carbonitrile
Step 1: 3- (5- (3-cyano-6- (2, 2-difluoroethylamino) pyrazolo [1,5-a ] pyridin-4-yl) pyridin-2-yl) -3, 6-diazabicyclo [3.1.1] heptane-6-carbamic acid tert-butyl ester
The compound was synthesized as in step 5 of example 1. The intermediate 1 and 2, 2-difluoroethylamine are used as raw materials for synthesis. The yield thereof was found to be 61%.
MS m/z:496.2[M+1]+。
Step 2: 4- (6- (3, 6-diazabicyclo [3.1.1] heptan-3-yl) pyridin-3-yl) -6- (2, 2-difluoroethylamino) pyrazolo [1,5-a ] pyridine-3-carbonitrile
To a 25ml three-necked flask were added tert-butyl 3- (5- (3-cyano-6- (2, 2-difluoroethylamino) pyrazolo [1,5-a ] pyridin-4-yl) pyridin-2-yl) -3, 6-diazabicyclo [3.1.1] heptane-6-carbamate (245mg, 0.50mmol) and 5ml of a 4.0M methanolic hydrogen chloride solution, and reacted at 25 ℃ overnight. And the MS monitors the completion of the reaction. The reaction solution was drained and acetonitrile was taken with water three times to obtain 300mg of crude 4- (6- (3, 6-diazabicyclo [3.1.1] heptane-3-yl) pyridin-3-yl) -6- (2, 2-difluoroethylamino) pyrazolo [1,5-a ] pyridine-3-carbonitrile. The yield thereof was found to be 99%.
MS m/z:396.2[M+1]+。
And step 3: 4- (6- (6- (2-fluoro-5-methoxybenzyl) -3, 6-diazabicyclo [3.1.1] heptan-3-yl) pyridin-3-yl) -6- (2, 2-difluoroethylamino) pyrazolo [1,5-a ] pyridine-3-carbonitrile
The synthesis of this compound was the same as in step 4 of example 1. Synthesized from intermediate 3A and 2-fluoro-5-methoxybenzaldehyde. The yield thereof was found to be 23%.
MS m/z:534.2[M+1]+。
1H NMR(400MHz,DMSO-d6)δ8.43(s,1H),8.35(d,J=2.2,1H), 8.24(d,J=1.6,1H),7.79(dd,J=8.7,2.2,1H),7.18(d,J=1.8,1H),7.06(d, J=8.3,2H),6.81(t,J=8.1,2H),6.41(t,J=6.5,1H),6.22(t,J=3.7,1H), 3.75(s,3H),3.75-3.54(m,11H),2.60(s,1H),1.63(s,1H).
Example 15: 4- (6- (6- (4-methoxybenzyl) -3, 6-diazabicyclo [3.1.1] heptan-3-yl) pyridin-3-yl) -6- (2-fluoroethylamino) pyrazolo [1,5-a ] pyridine-3-carbonitrile
Step 1: 3- (5- (6- ((tert-Butoxycarbonyl) amino) -3-cyanopyrazol [1,5-a ] pyridin-4-yl) pyridin-2-yl) -3, 6-diazabicyclo [3.1.1] heptane-6-carbamic acid tert-butyl ester
To a 100ml single neck flask was added tert-butyl 3- (5- (6-bromo-3-cyanopyrazole [1,5-a ] pyridin-4-yl) pyridin-2-yl) -3, 6-diazabicyclo [3.1.1] heptane-6-carbamate (635mg, 1.28 mmol), tris (dibenzylideneacetone) dipalladium (118mg, 0.13mmol), dicyclohexyl [3, 6-dimethoxy-2 ', 4', 6 '-triisopropyl [1, 1' -biphenyl ] -2-yl ] phosphine (69mg, 0.13mmol), cesium carbonate (1.26g, 3.84mmol), tert-butyl carbamate (453mg, 3.84mmol) and 15ml dioxane, under argon protection, and reacted at 90 ℃ overnight. Kieselguhr for filtration, evaporation of the filtrate under reduced pressure and chromatography on silica gel (dichloromethane: methanol ═ 30: 1) to give 488mg of the product tert-butyl 3- (5- (6- ((tert-butoxycarbonyl) amino) -3-cyanopyrazole [1,5-a ] pyridin-4-yl) pyridin-2-yl) -3, 6-diazabicyclo [3.1.1] heptane-6-carbamate. The yield thereof was found to be 71%.
MS m/z:532.3[M+1]+。
1H NMR(400MHz,CDCl3)δ9.12(s,1H),8.36(s,1H),8.23(s,1H), 7.76(d,J=7.3,1H),7.10(s,1H),6.67(t,J=7.3,2H),4.32(d,J=4.5,2H), 4.23-4.07(m,2H),3.59-3.47(m,2H),2.69(d,J=6.5,1H),1.55(s,9H), 1.43(s,1H),1.39(s,9H).
Step 2: 3- (5- (6- ((tert-Butoxycarbonyl) (2-fluoroethyl) amino) -3-cyanopyrazol [1,5-a ] pyridin-4-yl) pyridin-2-yl) -3, 6-diazabicyclo [3.1.1] heptane-6-carbamic acid tert-butyl ester
To a 250ml single neck flask was added tert-butyl 3- (5- (6- ((tert-butoxycarbonyl) amino) -3-cyanopyrazole [1,5-a ] pyridin-4-yl) pyridin-2-yl) -3, 6-diazabicyclo [3.1.1] heptane-6-carbamate (2900mg, 5.46mmol), cesium carbonate (5340mg, 16.4mmol), 1-fluoro-2-iodoethane (1430mg, 8.17mmol) and 100ml DMF, and reacted at 80 ℃ for 12 hours under nitrogen. The reaction mixture was quenched by addition of 150ml of water, and extracted three times with ethyl acetate (150 ml). The organic layer was evaporated to dryness under reduced pressure and chromatographed on crude silica gel (dichloromethane: methanol 30: 1) to give 2820mg of the product. The yield thereof was found to be 89%.
MS m/z:578.3[M+1]+。
1H NMR(400MHz,CDCl3)δ8.57(s,1H),8.37(d,J=1.8,1H),8.28(s, 1H),7.76(d,J=8.2,1H),7.30(s,1H),6.68(d,J=8.7,1H),4.69(dt,J= 47.5,4.5Hz,2H),4.32(d,J=4.6,2H),4.12(dd,J=14.3,7.1,2H),3.94(dt, J=26.5,4.6Hz,2H)3.57(s,2H),2.69(dd,J=13.7,6.2,1H),1.53(s,1H), 1.48(s,9H),1.39(s,9H).
And step 3: 4- (6- (3, 6-diazabicyclo [3.1.1] heptan-3-yl) pyridin-3-yl) -6- (2-fluoroethylamino) pyrazolo [1,5-a ] pyridine-3-carbonitrile
To a 250ml single neck flask were added tert-butyl 3- (5- (6- ((tert-butoxycarbonyl) (2-fluoroethyl) amino) -3-cyanopyrazol [1,5-a ] pyridin-4-yl) pyridin-2-yl) -3, 6-diazabicyclo [3.1.1] heptane-6-carbamate (2820mg, 4.88mmol) and 50ml of a 4.0M ethyl hydrogen chloride solution in ethyl acetate, and reacted under argon at 25 ℃ for 2 hours. The reaction mixture was evaporated to dryness under reduced pressure, 200ml of dichloromethane and 100ml of saturated sodium bicarbonate were added, stirred until no air bubbles were present and the organic layer was separated, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. Silica gel column chromatography (dichloromethane: methanol 15: 1) afforded the product. The yield thereof was found to be 80%.
MS m/z:378.2[M+1]+。
And 4, step 4: 4- (6- (6- (4-methoxybenzyl) -3, 6-diazabicyclo [3.1.1] heptan-3-yl) pyridin-3-yl) -6- (2-fluoroethylamino) pyrazolo [1,5-a ] pyridine-3-carbonitrile
To a 25ml three-necked flask were added 4- (6- (3, 6-diazabicyclo [3.1.1] heptan-3-yl) pyridin-3-yl) -6- (2-fluoroethylamino) pyrazolo [1,5-a ] pyridine-3-cyano (60mg, 0.16mmol), 4-methoxybenzaldehyde (18mg, 0.13mmol) and 6ml dichloroethane, and sodium triacetoxyborohydride (140mg, 0.66mmol) was slowly added, reacted at room temperature overnight with TLC monitoring of completion of the reaction. Quenching reaction by saturated sodium bicarbonate, washing by water, extracting by dichloromethane, drying an organic phase, draining, and carrying out silica gel column chromatography to obtain 4- (6- (6- (4-methoxybenzyl) -3, 6-diazabicyclo [3.1.1] heptane-3-yl) pyridine-3-yl) -6- (2-fluoroethylamino) pyrazole [1,5-a ] pyridine-3-cyano.
MS m/z:498.2[M+1]+。
1H NMR(400MHz,DMSO-d6)δ8.41(s,1H),8.35(d,J=1.9,1H), 8.10(d,J=1.2,1H),7.80(d,J=7.5,1H),7.31(s,2H),7.14(d,J=1.4,1H), 6.90(s,2H),6.80(d,J=8.8,1H),6.30(t,J=5.6,1H),4.62(dt,J=47.7,4.7 Hz,1H),4.16-3.86(m,4H),3.74(s,3H),3.68-3.44(m,4H),3.43-3.37 (m,2H),2.61(s,1H),1.66(s,1H).
Example 16: 4- (6- (6- ((5-fluoro-6-methoxypyridin-3-yl) methyl) -3, 6-diazabicyclo [3.1.1] heptan-3-yl) pyridin-3-yl) -6- (2-fluoroethylamine) -pyrazolo [1,5-a ] pyridine-3-carbonitrile
The compound was synthesized as in example 15. The intermediate 3B and 5-fluoro-6-methoxy nicotinaldehyde are taken as raw materials for synthesis.
MS m/z:517.1[M+1]+。
1H NMR(400MHz,DMSO-d6)δ8.41(s,1H),8.34(d,J=2.5Hz,1H), 8.10(d,J=1.9Hz,1H),7.93(s,1H),7.78(dd,J=8.8,2.5Hz,1H),7.64(d,J=11.5Hz,1H),7.12(d,J=2.0Hz,1H),6.78(d,J=8.8Hz,1H),6.27(t, J=5.9Hz,1H),4.63(dt,J=47.7,4.6Hz,2H),3.92(s,3H),3.71(s,4H), 3.54(s,4H),3.43(ddd,J=28.5,9.9,5.0Hz,2H),2.55(s,1H),1.59(d,J= 8.0Hz,1H).
Example 17: 4- (6- (6- (3, 5-difluoro-4-methoxybenzyl) -3, 6-diazabicyclo [3.1.1] heptan-3-yl) pyridin-3-yl) -6- (2-fluoroethylamino) pyrazolo [1,5-a ] pyridine-3-carbonitrile
The compound was synthesized as in example 15. The intermediate 3B and the 3, 5-difluoro-4-methoxybenzaldehyde are used as raw materials for synthesis.
MS m/z:534.2[M+1]+。
1H NMR(400MHz,DMSO-d6)δ8.40(s,1H),8.32(d,J=2.3,1H),8.08(d,J=1.5,1H),7.77(dd,J=8.8,2.4,1H),7.41-7.34(m,1H),7.12(d, J=8.2,2H),6.77(d,J=8.8,1H),6.27(t,J=5.8,1H),4.62(dt,J=47.7,4.7 Hz,2H),3.87(s,3H),3.72-3.65(m,4H),3.69-3.50(m,6H),2.56(dd, J=12.9,6.6,1H),1.64(s,1H).
Example 18: 4- (6- (6- (2-fluoro-4-methoxybenzyl) -3, 6-diazabicyclo [3.1.1] heptan-3-yl) pyridin-3-yl) -6- (2-fluoroethylamino) pyrazolo [1,5-a ] pyridine-3-carbonitrile
The compound was synthesized as in example 15. The intermediate 3B and the 2-fluoro-4-methoxybenzaldehyde are used as raw materials for synthesis. The yield thereof was found to be 37%.
MS m/z:516.2[M+1]+。
1H NMR(400MHz,DMSO-d6)δ8.41(s,1H),8.35(d,J=2.2,1H), 8.10(d,J=1.7,1H),7.79(dd,J=8.7,1.9,1H),7.40(s,1H),7.14(d,J=1.7, 1H),6.78(t,J=8.3,3H),6.25(t,J=5.8,1H),4.69(t,J=4.7,1H),4.57(t, J=4.7,1H),3.73(s,3H),3.73-3.37(m,10H),2.59(s,1H),1.62(s,1H).
Example 19: 4- (6- (6- (4- (difluoromethoxy) benzyl) -3, 6-diazabicyclo [3.1.1] heptan-3-yl) pyridin-3-yl) -6- (2-fluoroethylamino) pyrazolo [1,5-a ] pyridine-3-carbonitrile
The compound was synthesized as in example 15. The intermediate 3B and the 4- (difluoromethoxy) benzaldehyde are taken as raw materials for synthesis. The yield thereof was found to be 24%.
MS m/z:534.2[M+1]+。
1H NMR(400MHz,DMSO-d6)δ8.41(s,1H),8.35(d,J=2.1,1H), 8.10(d,J=1.5,1H),7.79(d,J=8.5,1H),7.42(s,2H),7.25-6.98(m,4H), 6.77(t,J=11.7,1H),6.25(t,J=5.8,1H),4.69(t,J=4.7,1H),4.57(t,J=4.7, 1H),3.82-3.37(m,10H),2.57(s,1H),1.63(s,1H).
Example 20: 4- (6- (6- ((6- (difluoromethoxy) pyridin-3-yl) methyl) -3, 6-diazabicyclo [3.1.1] heptan-3-yl) pyridin-3-yl) -6- (2-fluoroethylamino) pyrazolo [1,5-a ] pyridine-3-carbonitrile
The compound was synthesized as in example 15. The intermediate 3B and the 6- (difluoromethoxy) nicotinaldehyde are taken as raw materials for synthesis. The yield thereof was found to be 29%.
MS m/z:535.2[M+1]+。
1H NMR(400MHz,DMSO-d6)δ8.41(s,1H),8.35(d,J=2.2,1H), 8.21(s,1H),8.10(d,J=1.6,1H),7.91(d,J=7.8,1H),7.79(dd,J=8.8,2.4, 1H),7.68(s,1H),7.12(d,J=1.7,1H),7.04(d,J=8.4,1H),6.79(d,J=8.8, 1H),6.25(t,J=5.8,1H),4.69(t,J=4.7,1H),4.57(t,J=4.7,1H),3.82-3.37 (m,10H),2.55(s,1H),1.61(d,J=7.7,1H).
Example 21: 4- (6- (6- ((3-fluoro-4- (difluoromethoxy) benzyl) -3, 6-diazabicyclo [3.1.1] heptan-3-yl) pyridin-3-yl) -6- (2-fluoroethylamino) pyrazolo [1,5-a ] pyridine-3-carbonitrile
The compound was synthesized as in example 15. The intermediate 3B and the 3-fluoro-4- (difluoromethoxy) benzaldehyde are taken as raw materials for synthesis. MS m/z: 552.2[ M + 1]]+。
1H NMR(400MHz,DMSO-d6)δ8.42(s,1H),8.34(d,J=2.2,1H), 8.10(d,J=1.5,1H),7.78(dd,J=8.8,2.4,1H),7.38(d,J=12.1,1H),7.29(t, J=8.2,1H),7.23(d,J=11.5,2H),7.13(d,J=1.6,1H),6.78(d,J=8.8,1H), 6.30(t,J=5.8,1H),4.63(dt,J=47.7,4.7Hz,2H),3.72-3.68(m,4H), 3.58-3.53(m,4H),3.43(ddd,J=27.3,9.5,4.5Hz,2H),2.57(dd,J=12.8, 6.6Hz,1H),1.60(d,J=8.4,1H).
Example 22: 4- (6- (6- ((2, 3-difluoro-4- (methoxy) benzyl) -3, 6-diazabicyclo [3.1.1] heptan-3-yl) pyridin-3-yl) -6- (2-fluoroethylamino) pyrazolo [1,5-a ] pyridine-3-carbonitrile
The compound was synthesized as in example 15. The intermediate 3B and the 2, 3-difluoro-4- (methoxyl) benzaldehyde are taken as raw materials for synthesis.
MS m/z:534.2[M+1]+。
Example 23: 4- (6- (6- ((2, 5-difluoro-4- (methoxy) benzyl) -3, 6-diazabicyclo [3.1.1] heptan-3-yl) pyridin-3-yl) -6- (2-fluoroethylamino) pyrazolo [1,5-a ] pyridine-3-carbonitrile
The compound was synthesized as in example 15. The intermediate 3B and the 2, 5-difluoro-4- (methoxyl) benzaldehyde are taken as raw materials for synthesis.
MS m/z:534.2[M+1]+。
1H NMR(400MHz,DMSO-d6)δ8.41(s,1H),8.34(d,J=2.3,1H), 8.10(d,J=1.7,1H),7.78(dd,J=8.8,2.5,1H),7.28(dd,J=12.0,7.0,1H),7.13(d,J=1.8,1H),7.06(dd,J=11.5,7.3,1H),6.77(d,J=8.8,1H),6.27(t, J=5.8,1H),4.62(dt,J=47.7,4.7Hz,2H),3.82(s,3H),3.74-3.68(m,4H), 3.60-3.40(m,6H),2.53(d,J=7.3,1H),1.58(d,J=8.4,1H).
Example 24: 4- (6- (6- ((3-chloro-4- (methoxy) benzyl) -3, 6-diazabicyclo [3.1.1] heptan-3-yl) pyridin-3-yl) -6- (2-fluoroethylamino) pyrazolo [1,5-a ] pyridine-3-carbonitrile
The compound was synthesized as in example 15. The intermediate 3B and the 3-chloro-4- (methoxyl) benzaldehyde are taken as raw materials for synthesis.
MS m/z:532.2[M+1]+、534。
1H NMR(400MHz,DMSO-d6)δ=8.42(s,1H),8.34(d,J=2.3,1H), 8.11(d,J=1.6,1H),7.78(dd,J=8.8,2.4,1H),7.41(s,1H),7.28(d,J=8.2, 1H),7.14(s,1H),7.07(d,J=8.5,1H),6.78(d,J=8.8,1H),6.31(d,J=4.1, 1H),4.63(dt,J=47.7,4.7Hz,2H),3.83(s,3H),3.69(s,4H),3.56-3.45(m, 4H),3.43-3.38(m,2H),2.57(s,1H),1.60(d,J=8.1,1H).
Example 25: 4- (6- (6- ((2-chloro-4- (methoxy) benzyl) -3, 6-diazabicyclo [3.1.1] heptan-3-yl) pyridin-3-yl) -6- (2-fluoroethylamino) pyrazolo [1,5-a ] pyridine-3-carbonitrile
The compound was synthesized as in example 15. The intermediate 3B and 2-chloro-4- (methoxyl) benzaldehyde are taken as raw materials for synthesis.
MS m/z:532.2[M+1]+、534。
1H NMR(400MHz,DMSO-d6)δ8.41(s,1H),8.34(d,J=2.2,1H), 8.11(d,J=1.6,1H),7.79(dd,J=8.7,2.3,1H),7.49(s,1H),7.15(d,J=1.0, 1H),7.00(s,1H),6.93(d,J=7.7,1H),6.79(d,J=8.8,1H),6.30(s,1H), 4.63(dt,J=47.7,4.7Hz,2H),3.83(s,3H),3.82-3.66(m,4H),3.61-3.51 (m,4H),3.49-3.38(m,2H),2.58(s,1H),1.62(s,1H).
Example 26: 4- (6- (6- ((5-chloro-6-methoxypyridin-3-yl) methyl) -3, 6-diazabicyclo [3.1.1] heptan-3-yl) pyridin-3-yl) -6- (2-fluoroethylamino) pyrazolo [1,5-a ] pyridine-3-carbonitrile
The compound was synthesized as in example 15. The intermediate 3B and 5-chloro-6-methoxy nicotinaldehyde are taken as raw materials for synthesis.
MS m/z:532.2[M+1]+、534.2。
Example 27: 6- (4, 4, 4-Triflubutamine) -4- (6- (6- ((6-methoxypyridin-3-yl) methyl) -3, 6-diazabicyclo [3.1.1] heptan-3-yl) pyridin-3-yl) pyrazolo [1,5-a ] pyridine-3-carbonitrile
The compound was synthesized as in example 12. Coupling the intermediate 2A with tert-butyl carbamate, carrying out nucleophilic substitution on the coupled intermediate and 1, 1, 1-trifluoro-4-iodobutane, and removing a protecting group to obtain the product.
MS m/z:563.2[M+1]+。
1H NMR(400MHz,DMSO)δ8.42(s,1H),8.36(d,J=2.3Hz,1H), 8.09(s,1H),8.03(d,J=1.6Hz,1H),7.79(dd,J=8.8,2.4Hz,1H),7.70(d, J=7.8Hz,1H),7.05(d,J=1.7Hz,1H),6.94-6.65(m,2H),6.11(t,J= 5.6Hz,1H),3.83(s,3H),3.79-3.65(m,4H),3.55(d,J=18.8Hz,4H), 3.16(dd,J=12.7,6.5Hz,3H),2.52(s,1H),2.48-2.33(m,3H),1.92- 1.74(m,2H),1.60(d,J=6.4Hz,1H).
Example 28: 6- (3-Methylsulfonylpropamine) -4- (6- (6- ((6-methoxypyridin-3-yl) methyl) -3, 6-diazabicyclo [3.1.1] heptan-3-yl) pyridin-3-yl) pyrazolo [1,5-a ] pyridine-3-carbonitrile
The compound was synthesized as in example 1. The intermediate 2A and the 3-methylsulfonylpropylamine are taken as raw materials for synthesis.
MS m/z:573.2[M+1]+。
1H NMR(400MHz,DMSO)δ8.42(s,1H),8.35(d,J=2.2Hz,1H), 8.07(d,J=11.5Hz,2H),7.79(dd,J=8.8,2.2Hz,1H),7.69(d,J=7.7Hz, 1H),7.04(s,1H),6.78(t,J=7.6Hz,2H),6.13(t,J=5.6Hz,1H),3.82(s, 3H),3.78-3.65(m,4H),3.51(s,4H),3.31-3.18(m,4H),3.00(s,3H), 2.52(s,1H),2.00(dd,J=14.6,7.1Hz,2H),1.59(d,J=7.1Hz,1H).
Example 29: 6- (3-Fluoropropylamine) -4- (6- (6- ((6-methoxypyridin-3-yl) methyl) -3, 6-diazabicyclo [3.1.1] heptan-3-yl) pyridin-3-yl) pyrazolo [1,5-a ] pyridine-3-carbonitrile
The compound was synthesized as in example 12. Coupling the intermediate 2A with tert-butyl carbamate, carrying out nucleophilic substitution with 1-fluoro-3-iodopropane, and removing protecting groups.
MS m/z:513.2[M+1]+。
Example 30: 6- (3, 3, 3-Trifluoropropylamine) -4- (6- (6- ((6-methoxypyridin-3-yl) methyl) -3, 6-diazabicyclo [3.1.1] heptan-3-yl) pyridin-3-yl) pyrazolo [1,5-a ] pyridine-3-carbonitrile
The compound was synthesized as in example 1. The intermediate 2A and the 3, 3, 3-trifluoropropylamine are taken as raw materials for synthesis.
MS m/z:549.2[M+1]+。
Example 31: 6- (2, 2, 3, 3, 3-Pentafluoropropylamine) -4- (6- (6- ((6-methoxypyridin-3-yl) methyl) -3, 6-diazabicyclo [3.1.1] heptan-3-yl) pyridin-3-yl) pyrazolo [1,5-a ] pyridine-3-carbonitrile
The compound was synthesized as in example 1. The intermediate 2A and the 2, 2, 3, 3, 3-pentafluoropropylamine are taken as raw materials for synthesis.
MS m/z:585.2[M+1]+。
1H NMR(400MHz,DMSO)δ8.46(s,1H),8.35(d,J=5.7Hz,2H), 8.08(s,1H),7.80(d,J=7.7Hz,1H),7.69(d,J=8.1Hz,1H),7.20(d,J= 1.6Hz,1H),6.78(t,J=9.4Hz,2H),6.53(t,J=6.8Hz,1H),4.17(td,J= 15.8,6.5Hz,2H),3.82(s,3H),3.78-3.62(m,4H),3.57-3.51(m,4H), 2.50(s,1H),1.59(d,J=8.0Hz,1H).
Example 32: 6- ((2- (1H-imidazol-1-yl) ethylamino) -4- (6- (6- ((6-methoxypyridin-3-yl) methyl) -3, 6-diazabicyclo [3.1.1] heptan-3-yl) pyridin-3-yl) pyrazolo [1,5-a ] pyridine-3-carbonitrile
The compound was synthesized as in example 1. The intermediate 2A and 2- (1H-imidazole-1-yl) ethylamine are taken as raw materials for synthesis.
MS m/z:547.2[M+1]+。
1H NMR(400MHz,DMSO)δ8.42(s,1H),8.34(d,J=1.9Hz,1H), 8.10(s,2H),7.78(dd,J=8.7,2.2Hz,1H),7.70(d,J=8.1Hz,2H),7.28(s, 1H),7.07(s,1H),6.91(s,1H),6.78(dd,J=8.6,4.2Hz,2H),6.20(t,J= 5.7Hz,1H),4.20(t,J=5.7Hz,2H),3.83(s,3H),3.78-3.65(m,4H),3.63 -3.51(m,4H),3.50-3.46(m,2H),2.56(s,1H),1.61(d,J=8.2Hz,1H).
Example 33: 6- ((2- (1H-1, 2, 4-triazol-1-yl) ethylamino) -4- (6- (6- ((6-methoxypyridin-3-yl) methyl) -3, 6-diazabicyclo [3.1.1] heptan-3-yl) pyridin-3-yl) pyrazolo [1,5-a ] pyridine-3-carbonitrile
The compound was synthesized as in example 1. The intermediate 2A and 2- (1H-1, 2, 4-triazole-1-yl) ethylamine are taken as raw materials for synthesis.
MS m/z:548.2[M+1]+。
1H NMR(400MHz,DMSO)δ8.54(s,1H),8.43(s,1H),8.35(d,J= 2.2Hz,1H),8.11(s,2H),8.01(s,1H),7.78(dd,J=8.7,2.1Hz,1H),7.70 (d,J=7.9Hz,1H),7.05(d,J=1.0Hz,1H),6.79(dd,J=8.5,3.3Hz,2H), 6.17(t,J=5.9Hz,1H),4.42(t,J=5.7Hz,2H),3.83(s,3H),3.77-3.74 (m,4H),3.60-3.56(m,6H),2.55(s,1H),1.61(s,1H).
Example 34: 6- ((2- (1H-1, 3, 4-triazol-1-yl) ethylamino) -4- (6- (6- ((6-methoxypyridin-3-yl) methyl) -3, 6-diazabicyclo [3.1.1] heptan-3-yl) pyridin-3-yl) pyrazolo [1,5-a ] pyridine-3-carbonitrile
The compound was synthesized as in example 1. The intermediate 2A and 2- (1H-1, 3, 4-triazole-1-yl) ethylamine are taken as raw materials for synthesis.
MS m/z:548.2[M+1]+。
1H NMR(400MHz,DMSO)δ8.55(s,2H),8.43(s,1H),8.35(d,J= 2.3Hz,1H),8.17(d,J=1.7Hz,1H),8.08(s,1H),7.78(dd,J=8.8,2.5Hz, 1H),7.68(dd,J=8.4,2.2Hz,1H),7.04(d,J=1.8Hz,1H),6.86-6.72(m, 2H),6.17(t,J=6.0Hz,1H),4.26(t,J=5.8Hz,2H),3.82(s,3H),3.74- 3.67(m,4H),3.57-3.51(m,6H),2.52(s,1H),1.59(d,J=8.3Hz,1H).
Example 35: 6- ((2- (4H-1, 2, 4-triazol-1-yl) ethylamino) -4- (6- (6- ((6-methoxypyridin-3-yl) methyl) -3, 6-diazabicyclo [3.1.1] heptan-3-yl) pyridin-3-yl) pyrazolo [1,5-a ] pyridine-3-carbonitrile
The compound was synthesized as in example 12. Coupling the intermediate 2A with tert-butyl carbamate, carrying out nucleophilic substitution on the coupled intermediate and 3- (2-iodoethyl) -1- ((2- (trimethylsilyl) ethoxy) methyl) -1H-1, 2, 4-triazole, and removing protective groups to obtain the product.
MS m/z:548.2[M+1]+。
Example 36: 6- ((2- (5-methyl-4H-1, 2, 4-triazol-3-yl) ethylamino) -4- (6- (6- ((6-methoxypyridin-3-yl) methyl) -3, 6-diazabicyclo [3.1.1] heptan-3-yl) pyridin-3-yl) pyrazolo [1,5-a ] pyridine-3-carbonitrile
The compound was synthesized as in example 12. Coupling the intermediate 2A and tert-butyl carbamate, carrying out nucleophilic substitution on the coupled intermediate and 3- (2-iodoethyl) -5-methyl-4H-1, 2, 4-triazole-4-tert-butyl carbamate, and removing a protecting group to obtain the product.
MS m/z:562.2[M+1]+。
Biological test example
Test example 1: inhibitory Activity on RET kinase
The inhibitory effect of compounds on RET kinase (purchased from Carna Biosciences, inc., cat # 08-159) was examined using the method of microfluidics chip technology-based Mobility Assay (Caliper Mobility Shift Assay) developed by Caliper corporation. The final concentrations tested for the compounds of the invention, BLU-667 and LOXO-292 were 2. mu.M or 10. mu.M starting, 10 concentrations at 3-fold dilution. 250nL of each compound at 100-fold final concentration was transferred to 384-well reaction plates using a dispenser Echo 550, 10. mu.L of kinase solution (RET kinase was diluted with buffer to a final concentration of 1 nM; buffer purchased from Sangyo pharmaceutical technology (Shanghai) Co., Ltd.) was added, and pre-incubation was performed at room temperature for 10 minutes (negative control wells contained 10. mu.L of buffer and 250nL of 100% DMSO; positive control wells contained 10. mu.L of kinase solution and 250nL of 100% DMSO). To the 384-well reaction plate, 15. mu.L of Adenosine Triphosphate (ATP) was added to a final concentration of 16. mu.M and 3. mu.M of peptide # 2 (purchased from Gill Biochemical (Shanghai) Co., Ltd., product No. 112394) as a fluorescent labeling substrate, and the reaction was initiated with the mixed solution. After 60 minutes of reaction at room temperature, 30. mu.L of a termination test solution (ethylenediaminetetraacetic acid was added to the buffer solution) was added to stop the kinase reaction. And reading the conversion rate by using an EZ Reader platform of a Caliper company, and converting the inhibition rate.
Percent inhibition (% mean of positive control conversion% -mean of each compound%)/(mean of positive control conversion% -mean of negative control conversion%).
The log value of the concentration is taken as an X axis, the inhibition rate% is taken as a Y axis, and a dose-effect curve is fitted by adopting the log (inhibitor) vs. stress-Variable slope of the GraphPad Prism 5 analysis software, so that the IC of each compound on the enzyme activity is obtained50The values, results are shown in Table 1.
TABLE 1
Note: LOXO-292 reference WO2018071447A1 example 163 preparation
BLU-667 reference WO2017079140A1 example 130 preparation
Test results show that the compound has good inhibitory activity on RET kinase.
Test example 2: proliferation inhibitory activity against transfected cells Ba/F3 KIF5B-RET, Ba/F3 KIF5B-RET-G810R
The compound is used for determining the proliferation inhibition activity of the compound on Ba/F3 KIF5B-RET cell strain of a mouse protoB cell Ba/F3 stably expressing KIF5B-RET fusion protein and Ba/F3 KIF5B-RET-G810R cell strain of a mouse protoB cell Ba/F3 stably expressing KIF5B-RET fusion protein (the RET region is subjected to G810R point mutation).
Cell source: Ba/F3 KIF5B-RET cells were purchased from Congyuan Bo Chuang Biotechnology (Beijing) Ltd, cat # KC-1041; Ba/F3 KIF5B-RET-G810R cells were purchased from Congyuan Bo Chuang Biotechnology (Beijing) Ltd, cat # KC-1448.
Ba/F3 KIF5B-RET and Ba/F3 KIF5B-RET cells in logarithmic growth phase were seeded in 96-well plates (135. mu.l/well) and placed at 37 ℃ with 5% CO2The culture was carried out in a constant temperature incubator for 24 hours. The compounds of the present invention, BLU-667 and LOXO-292, had been dissolved in dimethyl sulfoxide (DMSO) beforehand to prepare 10mM stock solutions, and when assayed, were diluted 10 times the desired concentration in another 96-well plate with complete medium, and then 15. mu.l/well of each compound was added to the 96-well plate seeded with cells to reach the desired concentration. 3 replicate wells were set for each concentration, and a DMSO blank was set. Continuing to contain 5% CO at 37 deg.C2The culture was carried out in a constant temperature incubator for 72 hours. The inoculated 96-well cell culture plate was taken out from the carbon dioxide incubator, 20. mu.l of thiazole blue (i.e., MTT) stock solution which had been previously dissolved in 0.9% physiological saline to prepare 5mg/ml and subjected to filtration sterilization was added to each well, and then 5% CO was contained at 37 ℃2Incubated in a constant temperature incubator for 4 hours. Mu.l of triple solution (100 ml of a prepared solution prepared by dissolving 10g of Sodium Dodecyl Sulfate (SDS), 5ml of isobutanol and 0.1ml of 36-38% hydrochloric acid in purified water) is added into each hole, the mixture is incubated at 37 ℃ until the precipitate is completely dissolved, and the optical density value OD is detected at the wavelength of 570nm and the inhibition ratio is calculated by data arrangement. Inhibition data were analyzed using GraphPad Prism 5.0 software, dose-effect curves were fitted using non-linear sigmoidal regression, and IC was calculated therefrom50The values and results are shown in Table 2.
Percent inhibition [ (% OD)Control group containing DMSO culture medium for 72 hours-OD72 hours Compound group)/(ODControl group containing DMSO culture medium for 72 hours-ODControl group containing DMSO culture medium at 0 hour)]×100%。
TABLE 2
Note: ND means not determined
LOXO-292 reference WO2018071447A1 example 163 preparation
BLU-667 reference WO2017079140A1 example 130 preparation
Test results show that the compound has good proliferation inhibition activity on stably transfected cells Ba/F3 KIF5B-RET and Ba/F3 KIF 5B-RET-G810R; compared with BLU-667 and LOXO-292, the compound of the invention has better proliferation inhibition activity on the stable cells Ba/F3 KIF 5B-RET-G810R.
Test example 3: growth inhibition effect on stable cell Ba/F3 KIF5B-RET, Ba/F3 KIF5B-RET-G810R nude mouse subcutaneous transplantation tumor
The experiment is used for researching the growth inhibition effect and the safety condition of the compound on the subcutaneous transplantation tumor of the nude mice with the stable cells of Ba/F3 KIF5B-RET, Ba/F3 KIF 5B-RET-G810R.
Cell culture: the transfected cells Ba/F3 KIF5B-RET and Ba/F3 KIF5B-RET-G810R were each cultured in RPMI-1640 medium supplemented with 10% fetal bovine serum and placed at 37 ℃ in the presence of 5% CO2Culturing in a constant temperature incubator. Cells in the exponential growth phase were harvested and counted for inoculation.
Experimental animals: BALB/c Nude mice, female, 5 weeks old, 30, purchased from Experimental animals technologies, Inc., Wei Tong Li Hua, Beijing.
3 experimental groups are respectively arranged aiming at the stable transfected cell Ba/F3 KIF5B-RET and the stable transfected cell Ba/F3 KIF5B-RET-G810R, and each group comprises 5 cells; the 3 experimental groups were: vehicle control group (i.e., Vehicle group), LOXO-292 group and the compound of example 12 group containing 10% dimethylacetamide + 5% polyethylene glycol-15 hydroxystearate + 85% physiological saline.
Experimental protocol 3A: stable transfected cell Ba/F3 KIF5B-RET cell strain (2X 10)6One/only) inoculation in BALThe right dorsal part of B/c Nude mice was subcutaneously inoculated with 0.1mL of each mouse, and the growth of the tumor was observed periodically. When the tumor grows to be larger than 150mm3Time, groups were randomized according to tumor size. The LOXO-292 group and the compound group of example 12 were each administered at 10mg/kg by gavage at a volume of 10uL/g, and the vehicle control group was given an equivalent amount of vehicle twice daily for 14 consecutive days. Throughout the experiment, the body weight and tumor size of the mice were measured twice a week to see if a toxic reaction occurred.
Experimental protocol 3B: stable transfected cell Ba/F3 KIF5B-RET-G810R cell line (2X 10)6One by one) was inoculated subcutaneously into the right dorsal side of BALB/c Nude mice, each mouse was inoculated with 0.1mL, and the growth of tumors was observed periodically. When the tumor grows to be larger than 150mm3Time, groups were randomized according to tumor size. The LOXO-292 group and the compound group of example 12 were each administered at 30mg/kg by gavage at a volume of 10uL/g, and the vehicle control group was given an equivalent amount of vehicle twice daily for 14 consecutive days. Throughout the experiment, the body weight and tumor size of the mice were measured twice a week to see if a toxic reaction occurred.
The Tumor Volume (Tumor Volume, TV) is calculated as: TV is 1/2 × a × b × b, where a and b represent tumor length and width, respectively.
As a result: animals in both vehicle control groups in protocols 3A, 3B died after 7 days, whereas animals did not die in LOXO-292 and the example 12 compound groups and there was no significant weight loss during dosing; the tumor volume change curves of 3 experimental groups in experimental protocols 3A, 3B are shown in fig. 1 and fig. 2, respectively.
Test results show that the compound has good inhibition effect on the growth of subcutaneous transplantation tumor of nude mice with stable cells of Ba/F3 KIF5B-RET and Ba/F3 KIF 5B-RET-G810R; compared with LOXO-292, the compound has better inhibition effect on the growth of the subcutaneous transplantation tumor of the Ba/F3 KIF5B-RET-G810R nude mice; the compound has small influence on the body weight of a nude mouse and shows better safety.
All documents mentioned herein are incorporated by reference into this application. It should also be noted that various modifications, adaptations, and alternatives may occur to one skilled in the art without departing from the spirit and scope of the present invention after reading the foregoing disclosure of the present application, and such variations should fall within the scope of the present invention as set forth in the appended claims.
Claims (23)
1. A compound represented by the following formula (I) or a pharmaceutically acceptable salt thereof,
wherein:
x is selected from CR6Or N;
y is selected from CR6Or N;
z is selected from CR6Or N;
wherein 0, 1 or 2 of X, Y, Z are N;
R1selected from hydrogen, 6-10 membered aryl or 5-12 membered heteroaryl, wherein each of said 6-10 membered aryl or 5-12 membered heteroaryl is optionally substituted with 1, 2, 3 or 4 substituents each independently selected from hydroxy, halogen, C1-6Alkyl radical, C1-6Alkoxy, halo C1-6Alkyl, halo C1-6Alkoxy, hydroxy C1-6Alkyl, 3-6 membered cycloalkyl, cyano, -NR7R8or-O- (CH)2)n-NR7R8Substituted with the substituent(s);
R2selected from hydrogen, C1-4Alkyl or halo C1-4An alkyl group;
R3selected from hydrogen, C1-6Alkyl, 3-6 membered cycloalkyl, 3-8 membered heterocyclyl or 5-12 membered heteroaryl, wherein said C1-6Alkyl, 3-6 membered cycloalkyl, 3-8 membered heterocyclyl or 5-12 membered heteroaryl are each optionally substituted with 1, 2, 3 or 4 substituents each independently selected from halogen, C1-4Alkyl radical, C1-4Alkoxy, halo C1-4Alkyl, halo C1-4Alkoxy, cyano, hydroxy C1-4Alkyl, -C (═ O) -NR7R8、-SO2-C1-4Alkyl, 5-6 membered heteroaromaticOr 3-6 membered heterocyclyl, wherein said 5-6 membered heteroaryl or 3-6 membered heterocyclyl are each optionally substituted with 1, 2 or 3 substituents each independently selected from halogen, hydroxy, C1-4Alkyl radical, C1-4Alkoxy- (CH)2)m-or-C (═ O) -C1-4Alkyl is substituted by a substituent;
R4selected from hydrogen, C1-4Alkyl or halo C1-4An alkyl group;
R5selected from hydrogen, halogen, cyano, C1-4Alkyl or halo C1-4An alkyl group;
each R6Independently selected from H, C1-4Alkyl radical, C1-4Alkoxy, halo C1-4Alkyl or halogen;
each R7Independently selected from H, C1-4Alkyl or halo C1-4An alkyl group;
each R8Independently selected from H, C1-4Alkyl or halo C1-4An alkyl group;
n is selected from 1, 2 or 3;
m is selected from 0, 1, 2 or 3.
2. A compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein X is CR6Y is CR6Z is CR6Wherein each R is6Is H.
3. A compound according to any one of claims 1-2, or a pharmaceutically acceptable salt thereof, wherein R1Selected from phenyl or 5-6 membered heteroaryl, wherein said phenyl or 5-6 membered heteroaryl is each optionally substituted with 1, 2 or 3 substituents each independently selected from hydroxy, halogen, C1-6Alkyl radical, C1-6Alkoxy, halo C1-6Alkyl, halo C1-6Alkoxy or cyano.
4. A compound according to any one of claims 1 to 3, or a pharmaceutically acceptable salt thereof, wherein R1Selected from phenyl, pyridyl, pyrimidinyl, pyrazinyl, pyrrolylImidazolyl or thiazolyl, wherein the phenyl, pyridyl, pyrimidinyl, pyrazinyl, pyrrolyl, imidazolyl or thiazolyl is each optionally substituted with 1, 2 or 3 each independently selected from hydroxy, halogen, C1-4Alkyl radical, C1-4Alkoxy, halo C1-4Alkyl or halo C1-4Substituted by a substituent of alkoxy.
5. A compound according to any one of claims 1 to 4, or a pharmaceutically acceptable salt thereof, wherein R1Selected from phenyl, Wherein said phenyl group, Each optionally substituted by 1, 2 or 3 groups each independently selected from hydroxy, F, Cl, Br, C1-4Alkyl radical, C1-4Alkoxy, halo C1-4Alkyl or halo C1-4Substituted by a substituent of alkoxy.
6. A compound according to any one of claims 1 to 5, or a pharmaceutically acceptable salt thereof, wherein R1Selected from phenyl, Wherein said phenyl group, Each optionally substituted with 1, 2 or 3 substituents each independently selected from hydroxy, F, Cl, Br, methyl, ethyl, n-propyl, isopropyl, methoxy, ethoxy, n-propoxy, isopropoxy, monofluoromethyl, difluoromethyl, trifluoromethyl, CF3CH2-、CHF2CH2-、CH2FCH2-, monofluoromethoxy, difluoromethoxy, trifluoromethoxy, CF3CH2-O-、CHF2CH2-O-or CH2FCH2-O-is substituted.
8. A compound according to any one of claims 1 to 7, or a pharmaceutically acceptable salt thereof, wherein R2Selected from hydrogen or C1-4An alkyl group.
9. A compound according to any one of claims 1 to 8, or a pharmaceutically acceptable salt thereof, wherein R4Selected from hydrogen or C1-4An alkyl group.
10. A compound according to any one of claims 1 to 9, or a pharmaceutically acceptable salt thereof, wherein R5Selected from hydrogen, halogen or cyano.
11. A compound according to any one of claims 1 to 10, or a pharmaceutically acceptable salt thereof, wherein R3Selected from hydrogen, C1-6Alkyl or 3-6 membered cycloalkyl, wherein said C is1-6Alkyl orEach 3-6 membered cycloalkyl is optionally substituted by 1, 2 or 3 substituents each independently selected from halogen, C1-4Alkyl radical, C1-4Alkoxy, halo C1-4Alkyl, halo C1-4Alkoxy, cyano, hydroxy, -SO2-C1-4Alkyl, 5-6 membered heteroaryl or 3-6 membered heterocyclyl, wherein each of said 5-6 membered heteroaryl or 3-6 membered heterocyclyl is optionally substituted with 1, 2 or 3 substituents each independently selected from halogen, hydroxy or C1-4Alkyl substituents.
12. A compound according to any one of claims 1 to 11, or a pharmaceutically acceptable salt thereof, wherein R3Selected from hydrogen, C1-4Alkyl, cyclopropyl, cyclobutyl or cyclopentyl, wherein said C1-4Alkyl, cyclopropyl, cyclobutyl or cyclopentyl is each optionally substituted by 1, 2 or 3 substituents each independently selected from F, Cl, Br, C1-4Alkyl radical, C1-4Alkoxy, halo C1-4Alkyl, halo C1-4Alkoxy, cyano, hydroxy, -SO2-C1-4Alkyl, aryl, heteroaryl, and heteroaryl, Wherein said substituent is substituted, wherein Each optionally substituted by 1, 2 or 3 substituents each independently selected from F, Cl, Br, hydroxy or C1-4Taking of alkyl groupsSubstituted by substituent groups.
13. A compound according to any one of claims 1 to 12, or a pharmaceutically acceptable salt thereof, wherein R3Selected from hydrogen, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, cyclopropyl, cyclobutyl or cyclopentyl, wherein the methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, cyclopropyl, cyclobutyl or cyclopentyl are each optionally substituted with 1, 2 or 3 substituents each independently selected from F, Cl, Br, methyl, ethyl, methoxy, ethoxy, monofluoromethyl, difluoromethyl, trifluoromethyl, CF, and3CH2-、CHF2CH2-、CH2FCH2-, monofluoromethoxy, difluoromethoxy, trifluoromethoxy, CF3CH2-O-、CHF2CH2-O-、CH2FCH2-O-, cyano, hydroxy, -SO2-CH3、-SO2-CH2CH3、 Wherein said substituent is substituted, wherein Each optionally substituted with 1, 2 or 3 substituents each independently selected from F, Cl, Br, hydroxy, methyl or ethyl.
16. a process for preparing a compound of formula (I) comprising:
wherein R is1、R2、R3、R4、R5X, Y, Z is as defined in any one of claims 1 to 14; l is a leaving group selected from halogen; p is an amino protecting group, each P may be the same or different and is independently selected from t-butyloxycarbonyl, benzyloxycarbonyl or benzyl;
taking a compound a-1 and a compound a-2 as initial raw materials, and carrying out Suzuki coupling reaction to obtain a compound a-3; carrying out substitution reaction on the compound a-3 and the compound a-4 to obtain an intermediate 1; deprotection of the intermediate 1 to obtain a compound a-5; carrying out reductive amination reaction on the compound a-5 and the compound a-6 to obtain an intermediate 2; intermediate 2 andcarrying out coupling reaction to obtain a compound shown as a formula (I);
or intermediate 2 with P-NH2Carrying out coupling reaction to obtain a compound a-7; compounds a-7 and R3-L undergoes a substitution reaction to give a compound a-8; deprotection of the compound a-8 can obtain the compound shown in the formula (I).
17. A process for preparing a compound of formula (I) comprising:
wherein R is1、R2、R3、R4、R5X, Y, Z is as defined in any one of claims 1 to 14; l is a leaving group selected from halogen; p is an amino protecting group, each P may be the same or different and is independently selected from t-butyloxycarbonyl, benzyloxycarbonyl or benzyl;
intermediate 1 andcarrying out coupling reaction to obtain a compound b-1; deprotection of compound b-1 gives intermediate 3; carrying out reductive amination reaction on the intermediate 3 and a compound a-6 to obtain a compound shown in a formula (I);
or,intermediate 1 and P-NH2Carrying out coupling reaction to obtain a compound b-2; compounds b-2 and R3-L undergoes a substitution reaction to give a compound b-3; deprotecting compound b-3 to obtain intermediate 3; and carrying out reductive amination reaction on the intermediate 3 and the compound a-6 to obtain the compound shown in the formula (I).
18. An intermediate compound selected from the group consisting of compound a-7, compound a-8, compound b-1, compound b-2, compound b-3, and intermediate 3, as shown in the following structures,
wherein R is1、R2、R3、R4、R5X, Y, Z is as defined in any one of claims 1 to 14; p is an amino protecting group, each P may be the same or different and is independently selected from t-butyloxycarbonyl, benzyloxycarbonyl or benzyl.
19. A pharmaceutical composition comprising a compound of any one of claims 1-15, or a pharmaceutically acceptable salt thereof, and optionally a pharmaceutically acceptable carrier.
20. Use of a compound according to any one of claims 1 to 15, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition according to claim 19, in the manufacture of a medicament for the treatment of a disease mediated by RET.
21. The use according to claim 20, wherein the RET is selected from wild-type RET, mutant RET, RET fusions; the mutant RET is selected from G810R mutant RET, M918T mutant RET, V804L mutant RET and V804M mutant RET, and the RET fusion is selected from KIF5B-RET fusion and CCDC6-RET fusion.
22. The use according to claim 20, wherein the disease is selected from cancer, irritable bowel syndrome.
23. Use of a compound of any one of claims 1-15, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of claim 19, in the manufacture of a medicament for the treatment of cancer.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010625119.3A CN113880865A (en) | 2020-07-01 | 2020-07-01 | Pyrazolo [1,5-a ] pyridine compound and preparation method and application thereof |
CN202180047203.4A CN115989230A (en) | 2020-07-01 | 2021-06-30 | Pyrazole [1,5-a ] pyridine compound and preparation method and application thereof |
PCT/CN2021/103358 WO2022002097A1 (en) | 2020-07-01 | 2021-06-30 | Pyrazolo[1,5-a]pyridine compound, preparation method therefor and use thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010625119.3A CN113880865A (en) | 2020-07-01 | 2020-07-01 | Pyrazolo [1,5-a ] pyridine compound and preparation method and application thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN113880865A true CN113880865A (en) | 2022-01-04 |
Family
ID=79012173
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010625119.3A Pending CN113880865A (en) | 2020-07-01 | 2020-07-01 | Pyrazolo [1,5-a ] pyridine compound and preparation method and application thereof |
CN202180047203.4A Pending CN115989230A (en) | 2020-07-01 | 2021-06-30 | Pyrazole [1,5-a ] pyridine compound and preparation method and application thereof |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202180047203.4A Pending CN115989230A (en) | 2020-07-01 | 2021-06-30 | Pyrazole [1,5-a ] pyridine compound and preparation method and application thereof |
Country Status (2)
Country | Link |
---|---|
CN (2) | CN113880865A (en) |
WO (1) | WO2022002097A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112778337A (en) * | 2019-11-08 | 2021-05-11 | 杭州邦顺制药有限公司 | 3,6 diazabicyclo [3.1.1] heptane derivatives as RET kinase inhibitors |
WO2023143486A1 (en) * | 2022-01-29 | 2023-08-03 | 深圳众格生物科技有限公司 | Salt, crystalline form, solvate and hydrate of compound |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI704148B (en) * | 2016-10-10 | 2020-09-11 | 美商亞雷生物製藥股份有限公司 | Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors |
TWI783057B (en) * | 2017-10-10 | 2022-11-11 | 美商絡速藥業公司 | Process for the preparation of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile |
KR20210100155A (en) * | 2018-12-07 | 2021-08-13 | 선샤인 레이크 파르마 컴퍼니 리미티드 | RET inhibitors, pharmaceutical compositions and uses thereof |
MX2021013846A (en) * | 2019-05-14 | 2022-03-22 | Shanghai Hansoh Biomedical Co Ltd | Inhibitor containing bicyclic derivative, preparation method therefor and use thereof. |
CN112778337B (en) * | 2019-11-08 | 2023-09-26 | 杭州邦顺制药有限公司 | 3, 6 diazabicyclo [3.1.1] heptane derivatives as RET kinase inhibitors |
CN112939967B (en) * | 2019-12-11 | 2024-08-27 | 深圳众格生物科技有限公司 | Pyrazolo [1,5-a ] pyridine compound, and preparation method and application thereof |
-
2020
- 2020-07-01 CN CN202010625119.3A patent/CN113880865A/en active Pending
-
2021
- 2021-06-30 WO PCT/CN2021/103358 patent/WO2022002097A1/en active Application Filing
- 2021-06-30 CN CN202180047203.4A patent/CN115989230A/en active Pending
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112778337A (en) * | 2019-11-08 | 2021-05-11 | 杭州邦顺制药有限公司 | 3,6 diazabicyclo [3.1.1] heptane derivatives as RET kinase inhibitors |
CN112778337B (en) * | 2019-11-08 | 2023-09-26 | 杭州邦顺制药有限公司 | 3, 6 diazabicyclo [3.1.1] heptane derivatives as RET kinase inhibitors |
TWI844244B (en) * | 2022-01-19 | 2024-06-01 | 大陸商深圳眾格生物科技有限公司 | Salts, crystal forms, solvents and hydrates of compounds |
WO2023143486A1 (en) * | 2022-01-29 | 2023-08-03 | 深圳众格生物科技有限公司 | Salt, crystalline form, solvate and hydrate of compound |
Also Published As
Publication number | Publication date |
---|---|
CN115989230A (en) | 2023-04-18 |
WO2022002097A1 (en) | 2022-01-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104860941B (en) | 2,4-disubstituted phenyl-1,5-diamine derivatives and use thereof, and pharmaceutical composition and medicinal composition prepared from 2,4-disubstituted phenyl-1,5-diamine derivative | |
KR20210121168A (en) | Heterocyclic compound benzopyridone and its use | |
KR102051609B1 (en) | 2-arylaminopyridine, pyrimidine or triazine derivatives and methods for their preparation and use | |
JP2022523274A (en) | JAK inhibitor compounds and their use | |
JP2016169161A (en) | Novel imidazo pyridine compound | |
CN113527335A (en) | Macrocyclic compound as EGFR inhibitor and application thereof | |
KR20150028999A (en) | 5-azaindazole compounds and methods of use | |
CN113330009B (en) | Azacyclic compounds, preparation method and application thereof | |
JP2017001991A (en) | Novel benzoxazolone compound | |
CN114656482A (en) | Macrocyclic heterocyclic compound as EGFR inhibitor and application thereof | |
WO2017006953A1 (en) | HETEROCYCLIC DERIVATIVE HAVING TrkA-INHIBITING ACTIVITY | |
EA027984B1 (en) | Amino-quinolines as rip2 kinase inhibitors | |
WO2018028664A1 (en) | Fgfr4 inhibitor and preparation method and use thereof | |
WO2021127397A1 (en) | Nitrogen heterocyclic compounds and methods of use | |
CN115989230A (en) | Pyrazole [1,5-a ] pyridine compound and preparation method and application thereof | |
US20230192734A1 (en) | Tricyclic compounds as egfr inhibitors | |
JPWO2017043636A1 (en) | Novel benzimidazole compounds and their pharmaceutical uses | |
JP2021501215A (en) | Amino-substituted nitrogen-containing condensed ring compound, its preparation method and use | |
US20240317730A1 (en) | Heteroaryl derivative compounds, and uses thereof | |
US20230115907A1 (en) | Heterocyclic compound and pharmaceutical composition, preparation method, intermediate and use thereof | |
CN111718332B (en) | 2-substituted pyrazol amino-4-substituted amino-5-pyrimidine formamide compound, composition and application thereof | |
US20220235070A1 (en) | Macrolide derivatives, preparation method and application thereof | |
US20240246940A1 (en) | Heteroaryl derivative compound and use thereof | |
CN115433207A (en) | Macrocyclic heterocyclic compound as EGFR inhibitor and application thereof | |
TWI749518B (en) | Piperazine amide derivative, its preparation method and its use in medicine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
CB02 | Change of applicant information |
Address after: No. 268 Lingxiaohua Road, Zhoupu Town, Pudong New Area, Shanghai, 201318 Applicant after: Shanghai ALLIST medicine Polytron Technologies Inc. Address before: 201203 5th floor, building 1, 1227 zhangheng road and 1118 HaLei Road, Pudong New Area Free Trade Zone, Shanghai Applicant before: Shanghai ALLIST medicine Polytron Technologies Inc. |
|
CB02 | Change of applicant information |